Art. -Nr.: HY-N0005

Curcumin

(Synonyms: Diferuloylmethane; Natural Yellow 3; Turmeric yellow)

135 Cited Publications

Kundenbewertung

Based on 135 publication(s) in Google Scholar

Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.63%
CAS. Nr.: 458-37-7
Formel: C₂₁H₂₀O₆
Molecular Weight:368.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Curcumin Chemical Structure

CAS. Nr.: 458-37-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (135)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

CBP/p300

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen :

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	5 μM Compound: curcumin	Cytotoxicity against cisplatin-sensitive human 2008 cells after 72 hrs by crystal violet dye assay Cytotoxicity against cisplatin-sensitive human 2008 cells after 72 hrs by crystal violet dye assay	[PMID: 19329324]
4T1	IC₅₀	20 μM Compound: 2	Cytotoxicity against mouse 4T1 cells by MTT assay Cytotoxicity against mouse 4T1 cells by MTT assay	[PMID: 26561365]
4T1	IC₅₀	49.4 μM Compound: Curcumin	Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
A2780	IC₅₀	11 μM Compound: Curcumin, CURC	Cytotoxicity against c-DDP-resistant human A2780 cells after 72 hrs by crystal violet dye assay Cytotoxicity against c-DDP-resistant human A2780 cells after 72 hrs by crystal violet dye assay	[PMID: 22029378]
A2780	IC₅₀	12 μM Compound: Curcumin, CURC	Cytotoxicity against human A2780 cells after 48 hrs by crystal violet dye assay Cytotoxicity against human A2780 cells after 48 hrs by crystal violet dye assay	[PMID: 22029378]
A2780	IC₅₀	18 μM Compound: Curcumin, CURC	Cytotoxicity against c-DDP-resistant human A2780 cells after 48 hrs by crystal violet dye assay Cytotoxicity against c-DDP-resistant human A2780 cells after 48 hrs by crystal violet dye assay	[PMID: 22029378]
A2780	IC₅₀	28 μM Compound: Curcumin, CURC	Cytotoxicity against c-DDP-resistant human A2780 cells after 24 hrs by crystal violet dye assay Cytotoxicity against c-DDP-resistant human A2780 cells after 24 hrs by crystal violet dye assay	[PMID: 22029378]
A2780	IC₅₀	38 μM Compound: Curcumin, CURC	Cytotoxicity against human A2780 cells after 24 hrs by crystal violet dye assay Cytotoxicity against human A2780 cells after 24 hrs by crystal violet dye assay	[PMID: 22029378]
A2780	IC₅₀	6.52 μg/mL Compound: Curcumin	Antiproliferative activity against human A2780 cells Antiproliferative activity against human A2780 cells	[PMID: 29432947]
A2780	IC₅₀	8 μM Compound: Curcumin, CURC	Cytotoxicity against human A2780 cells after 72 hrs by crystal violet dye assay Cytotoxicity against human A2780 cells after 72 hrs by crystal violet dye assay	[PMID: 22029378]
A-431	ED₅₀	0.75 μg/mL Compound: 5	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 17643301]
A-431	IC₅₀	>100 μM Compound: CUR	Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A-431	IC₅₀	13.8 μM Compound: Curcumin	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	[PMID: 21215629]
A-431	IC₅₀	22 μM Compound: Curcumin	Anticancer activity against Homo sapiens (human) A431 cells assessed as inhibition of cell viability after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) A431 cells assessed as inhibition of cell viability after 72 hr by MTT assay	10.1007/s00044-013-0510-y
A-431	IC₅₀	6000 nM Compound: K00009, Curcumin	Inhibition of nitric oxide synthase in activated macrophages in human A431 cells Inhibition of nitric oxide synthase in activated macrophages in human A431 cells	[PMID: 18077363]
A549	GI₅₀	15.23 μM Compound: 1, Curcumin	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21070043]
A549	GI₅₀	9.44 μM Compound: 1, Curcumin	Growth inhibition of human A549 cells after 72 hrs by alamar blue method Growth inhibition of human A549 cells after 72 hrs by alamar blue method	[PMID: 21070043]
A549	IC₅₀	>10 μM Compound: Curcumin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29886021]
A549	IC₅₀	0.2 μM Compound: 19	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
A549	IC₅₀	0.22 μM Compound: 4	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 preincubated for 15 mins by HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 preincubated for 15 mins by HPLC analysis	[PMID: 26588603]
A549	IC₅₀	0.6 μM Compound: 1	Inhibition of mPGES1-mediated PGE2 production in microsomes of IL-1beta stimulated human A549 cells preincubated for 15 mins by RP-HPLC analysis Inhibition of mPGES1-mediated PGE2 production in microsomes of IL-1beta stimulated human A549 cells preincubated for 15 mins by RP-HPLC analysis	[PMID: 24920381]
A549	IC₅₀	11.58 μM Compound: Curcumin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 22889562]
A549	IC₅₀	13 μM Compound: curcumin	Inhibition of NF-kappaB nuclear translocation in human A549 cells Inhibition of NF-kappaB nuclear translocation in human A549 cells	[PMID: 19854644]
A549	IC₅₀	15 μM Compound: 1, Curcumin	Cytotoxicity against human A549 cells after 5 days by trypan blue exclusion assay Cytotoxicity against human A549 cells after 5 days by trypan blue exclusion assay	[PMID: 24531225]
A549	IC₅₀	15.06 μM Compound: Curcumin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27816267]
A549	IC₅₀	17 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as loss of cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as loss of cell viability after 48 hrs by MTT assay	[PMID: 21830815]
A549	IC₅₀	17.3 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24280069]
A549	IC₅₀	17.9 μM Compound: Curcumin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30138803]
A549	IC₅₀	18 μM Compound: Curc	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	20.3 μM Compound: Curcumin	Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay	[PMID: 22137846]
A549	IC₅₀	21.36 μM Compound: Curcumin	Inhibition of TNFalpha-induced NF-kappaB translocation in human A549 cells incubated at 37 degC for 30 mins by high content analysis based immunofluorescence assay Inhibition of TNFalpha-induced NF-kappaB translocation in human A549 cells incubated at 37 degC for 30 mins by high content analysis based immunofluorescence assay	[PMID: 22889562]
A549	IC₅₀	22 μM Compound: Curcumin	Anticancer activity against Homo sapiens (human) A549 cells assessed as inhibition of cell viability after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) A549 cells assessed as inhibition of cell viability after 72 hr by MTT assay	10.1007/s00044-013-0510-y
A549	IC₅₀	23 μM Compound: Curcumin	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 28814374]
A549	IC₅₀	23.54 μM Compound: Curcumin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 26873414]
A549	IC₅₀	24.18 μM Compound: 4	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
A549	IC₅₀	24.59 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) A549 cell by MTT assay Cytotoxicity against Homo sapiens (human) A549 cell by MTT assay	10.1007/s00044-010-9353-y
A549	IC₅₀	25.33 μM Compound: 1; CUR	Cytotoxicity against human A549 Cells by MTT assay Cytotoxicity against human A549 Cells by MTT assay	[PMID: 31129455]
A549	IC₅₀	27 μM Compound: 23, Curcumin	Anticancer activity against human A549 cells after 24 hrs by MTT assay Anticancer activity against human A549 cells after 24 hrs by MTT assay	[PMID: 20466556]
A549	IC₅₀	27.8 μM Compound: CUR	Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
A549	IC₅₀	28 μM Compound: 1; CUR	Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay	[PMID: 31129455]
A549	IC₅₀	32.2 μM Compound: 1	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23357628]
A549	IC₅₀	32.5 μM Compound: 22	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 32172081]
A549	IC₅₀	35.82 μM Compound: H-CUR	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability Antiproliferative activity against human A549 cells assessed as inhibition of cell viability	[PMID: 38665827]
A549	IC₅₀	38.12 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26891099]
A549	IC₅₀	40.56 μM Compound: 2	Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
A549	IC₅₀	42.6 μM Compound: Curcumin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21215629]
A549	IC₅₀	43.9 μM Compound: CUR	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	44.75 μM Compound: Curcumin	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
A549	IC₅₀	49.2 μM Compound: Curcumin	Cytotoxicity against human A549 cells after 72 hrs by crystal violet staining based microplate reader analysis Cytotoxicity against human A549 cells after 72 hrs by crystal violet staining based microplate reader analysis	[PMID: 23153397]
A549	IC₅₀	5.2 μg/mL Compound: 2	Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
A549	IC₅₀	52.3 μM Compound: 1; CUR	Cytotoxicity against human A549 Cells after 24 hrs by MTT assay Cytotoxicity against human A549 Cells after 24 hrs by MTT assay	[PMID: 31129455]
A549	IC₅₀	6.521 μg/mL Compound: Curcumin	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 29432947]
A549	IC₅₀	6.8 μM Compound: Curcumin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
A549	IC₅₀	60.2 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 26174555]
A549	IC₅₀	62.59 μM Compound: 8	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay Antiproliferative activity against human A549 cells after 48 hrs by MTS assay	[PMID: 22546674]
A549	IC₅₀	9.5 μM Compound: 1, Curcumin	Inhibition of TNF-alpha-induced NFkappaB nuclear translocation in human A549 cells preincubated for 30 mins before TNFalpha challenge and measured 30 post TNFalpha challenge by fluorescence method Inhibition of TNF-alpha-induced NFkappaB nuclear translocation in human A549 cells preincubated for 30 mins before TNFalpha challenge and measured 30 post TNFalpha challenge by fluorescence method	[PMID: 21070043]
A549/CDDP	IC₅₀	32.39 μM Compound: 2	Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay	[PMID: 26891099]
A549/CDDP	IC₅₀	39.42 μM Compound: 2	Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
A549/CDDP	IC₅₀	67.24 μM Compound: H-CUR	Antiproliferative activity against human A549/DDP cells assessed as inhibition of cell viability Antiproliferative activity against human A549/DDP cells assessed as inhibition of cell viability	[PMID: 38665827]
AGS	IC₅₀	20.76 μM Compound: 1; CUR	Cytotoxicity against human AGS Cells by MTT assay Cytotoxicity against human AGS Cells by MTT assay	[PMID: 31129455]
AGS	IC₅₀	9.77 μM Compound: 1; CUR	Cytotoxicity against human AGS Cells Cytotoxicity against human AGS Cells	[PMID: 31129455]
B16-F10	IC₅₀	10 μM Compound: 23, Curcumin	Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 20466556]
Bel-7402	IC₅₀	6.496 μg/mL Compound: Curcumin	Antiproliferative activity against human Bel7402 cells Antiproliferative activity against human Bel7402 cells	[PMID: 29432947]
BGC-823	IC₅₀	>20 μM Compound: 1; CUR	Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay	[PMID: 31129455]
BGC-823	IC₅₀	16.7 μM Compound: Cur, (Curcumin)	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19243951]
BGC-823	IC₅₀	17.5 μM Compound: 1; CUR	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 31129455]
BGC-823	IC₅₀	19.5 μM Compound: Curcumin	Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
BGC-823	IC₅₀	6.806 μg/mL Compound: Curcumin	Antiproliferative activity against human BGC823 cells Antiproliferative activity against human BGC823 cells	[PMID: 29432947]
Bone marrow cell	IC₅₀	7.5 μM Compound: Curcumin	Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay	[PMID: 26923696]
BT-474	IC₅₀	11 μM Compound: CU	Cytotoxicity against human BT474 cells Cytotoxicity against human BT474 cells	[PMID: 31336310]
BT-474	IC₅₀	30.14 μM Compound: Curcumin	Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay	[PMID: 28319780]
BT-549	IC₅₀	10.5 μM Compound: 1, curcumin, Diferuloylmethane	Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining	10.1007/s00044-011-9587-3
BT-549	IC₅₀	24.93 μM Compound: Curcumin	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay	[PMID: 28038323]
BV-2	CC₅₀	>50 μM Compound: Curcumin	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell growth Cytotoxicity against mouse BV-2 cells assessed as reduction in cell growth	[PMID: 37159940]
BV-2	IC₅₀	0.5 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse BV-2 cells by MTT assay Inhibition of LPS-induced NO production in mouse BV-2 cells by MTT assay	[PMID: 33454546]
BV-2	IC₅₀	0.5 μM Compound: Curcumin	Inhibition of NO production in LPS-stimulated mouse BV-2 cells preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay Inhibition of NO production in LPS-stimulated mouse BV-2 cells preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay	[PMID: 33454546]
BV-2	IC₅₀	0.5 μM Compound: curcumin	Inhibition of LPS-induced NO production in mouse BV2 cells compound pre-treated for 1 hr before LPS addition measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse BV2 cells compound pre-treated for 1 hr before LPS addition measured after 24 hrs by Griess assay	[PMID: 24593150]
BV-2	IC₅₀	0.52 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method	[PMID: 26859776]
BV-2	IC₅₀	0.53 μM Compound: curcumin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 24467317]
BV-2	IC₅₀	1.42 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay	[PMID: 27592135]
BV-2	IC₅₀	2.2 μM Compound: Curcumin	Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay	[PMID: 27617803]
BV-2	IC₅₀	2.36 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay	[PMID: 28032759]
BV-2	IC₅₀	2.69 μM Compound: Curcumin	Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced nitric oxide production by colorimetric assay Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced nitric oxide production by colorimetric assay	[PMID: 36346918]
BV-2	IC₅₀	3 μM Compound: Curcumin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO-production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by microplate reader based colorimetric assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO-production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by microplate reader based colorimetric assay	[PMID: 34185528]
BV-2	IC₅₀	3.1 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in human BV2 cells after 24 hrs by spectrophotometry Inhibition of LPS-induced nitric oxide production in human BV2 cells after 24 hrs by spectrophotometry	[PMID: 23734721]
BV-2	IC₅₀	3.9 μM Compound: Curcumin	Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production measured 24 hrs post LPS-challenge by spectrophotometry Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production measured 24 hrs post LPS-challenge by spectrophotometry	[PMID: 24256496]
BV-2	IC₅₀	3.9 μM Compound: Curcumin	Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 24 hrs before LPS-stimulation measured after 24 hrs Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 24 hrs before LPS-stimulation measured after 24 hrs	[PMID: 26241103]
BV-2	IC₅₀	4 μM Compound: Curcumin	Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 29035525]
BV-2	IC₅₀	4.5 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay	[PMID: 28055210]
BV-2	IC₅₀	4.77 μM Compound: Curcumin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27228227]
BV-2	IC₅₀	6 μM Compound: Curcumin	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method	[PMID: 28514148]
BV-2	IC₅₀	8.6 μM Compound: Curcumin	Antiinflammatory activity against mouse BV-2 cells assessed as reduction in LPS-induced NO production incubated for 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse BV-2 cells assessed as reduction in LPS-induced NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 37159940]
BXPC-3	IC₅₀	11.43 μM Compound: 8	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay	[PMID: 22546674]
BXPC-3	IC₅₀	18.25 μM Compound: 1; CUR	Cytotoxicity against human BxPC3 cells Cytotoxicity against human BxPC3 cells	[PMID: 31129455]
BXPC-3	IC₅₀	2.9 μM Compound: CCMN, curcurmin	Cytotoxicity against human BxPC3 cells Cytotoxicity against human BxPC3 cells	[PMID: 17973470]
BXPC-3	IC₅₀	29 μM Compound: Curc	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
C13	IC₅₀	16 μM Compound: Curcumin, CURC	Cytotoxicity against c-DDP-resistant human C13 cells after 72 hrs by crystal violet dye assay Cytotoxicity against c-DDP-resistant human C13 cells after 72 hrs by crystal violet dye assay	[PMID: 22029378]
C13	IC₅₀	17 μM Compound: curcumin	Cytotoxicity against cisplatin-resistant human C13 cells after 72 hrs by crystal violet dye assay Cytotoxicity against cisplatin-resistant human C13 cells after 72 hrs by crystal violet dye assay	[PMID: 19329324]
C13	IC₅₀	18 μM Compound: Curcumin, CURC	Cytotoxicity against c-DDP-resistant human C13 cells after 48 hrs by crystal violet dye assay Cytotoxicity against c-DDP-resistant human C13 cells after 48 hrs by crystal violet dye assay	[PMID: 22029378]
C13	IC₅₀	18 μM Compound: Curcumin, CURC	Cytotoxicity against human C13 cells after 24 hrs by crystal violet dye assay Cytotoxicity against human C13 cells after 24 hrs by crystal violet dye assay	[PMID: 22029378]
C13	IC₅₀	26 μM Compound: Curcumin, CURC	Cytotoxicity against c-DDP-resistant human C13 cells after 24 hrs by crystal violet dye assay Cytotoxicity against c-DDP-resistant human C13 cells after 24 hrs by crystal violet dye assay	[PMID: 22029378]
C13	IC₅₀	4.7 μM Compound: Curcumin, CURC	Cytotoxicity against human C13 cells after 72 hrs by crystal violet dye assay Cytotoxicity against human C13 cells after 72 hrs by crystal violet dye assay	[PMID: 22029378]
C13	IC₅₀	7 μM Compound: Curcumin, CURC	Cytotoxicity against human C13 cells after 48 hrs by crystal violet dye assay Cytotoxicity against human C13 cells after 48 hrs by crystal violet dye assay	[PMID: 22029378]
C6	IC₅₀	16.1 μM Compound: 1	Antiproliferative activity against rat C6 cells after 72 hrs by MTT assay Antiproliferative activity against rat C6 cells after 72 hrs by MTT assay	[PMID: 20831222]
Caco-2	IC₅₀	>25 μM Compound: 1a	Growth inhibition of differentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of differentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
Caco-2	IC₅₀	>25 μM Compound: 1a	Growth inhibition of differentiated human Caco2 cells measured after 72 hrs by SRB assay Growth inhibition of differentiated human Caco2 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
Caco-2	IC₅₀	>25 μM Compound: 1a	Growth inhibition of undifferentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of undifferentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
Caco-2	IC₅₀	>25 μM Compound: 1a	Growth inhibition of undifferentiated human Caco2 cells measured after 72 hrs by SRB assay Growth inhibition of undifferentiated human Caco2 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
Caco-2	IC₅₀	10.3 μM Compound: 7	Antiproliferative activity against human Caco2 cells Antiproliferative activity against human Caco2 cells	[PMID: 26539626]
Caco-2	IC₅₀	15 μM Compound: 1	Antiproliferative activity against human Caco-2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco-2 cells after 72 hrs by MTT assay	[PMID: 20831222]
Caco-2	IC₅₀	28 μM Compound: 1; CUR	Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay	[PMID: 31129455]
Caco-2	IC₅₀	38.3 μM Compound: 1a	Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
Caco-2	IC₅₀	47.6 μM Compound: Curcumin	Antiproliferative activity against human Caco-2 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human Caco-2 cells incubated for 96 hrs by MTT assay	[PMID: 38107170]
Caco-2	IC₅₀	48.6 μM Compound: curcumin	Cytotoxicity against human Caco-2 cells after 24 hrs by ATPLite assay Cytotoxicity against human Caco-2 cells after 24 hrs by ATPLite assay	[PMID: 20297825]
Caco-2	IC₅₀	8.5 μM Compound: 8, curcumin	Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography Reduction of MMP9 activity in TNF-alpha/IL1-beta-stimulated human Caco-2 cells treated 1 hr before stimulation by zymography	[PMID: 19128977]
CCD-18Co	GI₅₀	7.2 μg/mL Compound: Curc	Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent cell viability Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent cell viability	[PMID: 31767266]
CCD-841CoN	GI₅₀	58.6 μM Compound: 5	Cytotoxicity against human CRL1790 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B assay Cytotoxicity against human CRL1790 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B assay	[PMID: 28716495]
CCD-841CoN	IC₅₀	105.11 μM Compound: CU	Cytotoxicity against human CRL1790 cells Cytotoxicity against human CRL1790 cells	[PMID: 31336310]
CCRF-CEM	IC₅₀	10.51 μM Compound: Curcumin	Antiproliferative activity against human CCRF-CEM cells Antiproliferative activity against human CCRF-CEM cells	[PMID: 38889607]
CCRF-CEM	IC₅₀	15 μM Compound: Curcumin	Cytostatic activity against human CEM cells Cytostatic activity against human CEM cells	[PMID: 25577711]
CCRF-CEM	IC₅₀	8.16 μM Compound: Curcumin	Antiproliferative activity against human CEM cells after 72 hrs by coulter counting analysis Antiproliferative activity against human CEM cells after 72 hrs by coulter counting analysis	[PMID: 24657568]
CCRF-CEM	IC₅₀	8.7 μM Compound: 1, curcumin	Cytostatic activity against human CEM cells Cytostatic activity against human CEM cells	[PMID: 17768050]
CHO-K1	IC₅₀	>25 μM Compound: 1a	Growth inhibition of CHOK1 cells measured after 72 hrs by SRB assay Growth inhibition of CHOK1 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
CHO-K1	IC₅₀	21.3 μM Compound: 1; CUR	Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay	[PMID: 31129455]
CHO-K1	IC₅₀	42 μM Compound: 1a	Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CHO-K1	IC₅₀	7.5 μM Compound: 1a	Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
CNE	IC₅₀	32.8 μM Compound: Cur, (Curcumin)	Cytotoxicity against human CNE cells after 72 hrs by MTT assay Cytotoxicity against human CNE cells after 72 hrs by MTT assay	[PMID: 19243951]
CNE-2	IC₅₀	5.76 μM Compound: Curcumin	Antiproliferative activity against human CNE2 cells after 48 hrs by SRB assay Antiproliferative activity against human CNE2 cells after 48 hrs by SRB assay	[PMID: 22889562]
COLO 201	IC₅₀	18 μM Compound: Curc	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO 205	GI₅₀	12.7 μg/mL Compound: Curc	Growth inhibition of human COLO205 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability Growth inhibition of human COLO205 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability	[PMID: 31767266]
Colon 26	IC₅₀	30.34 μM Compound: CU	Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay	[PMID: 31336310]
CT26	IC₅₀	>20 μM Compound: 1; CUR	Cytotoxicity against mouse CT26 cells Cytotoxicity against mouse CT26 cells	[PMID: 31129455]
CT26	IC₅₀	7.7 μM Compound: CUR	Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
CWR22R	GI₅₀	14.3 μg/mL Compound: Curc	Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay	[PMID: 31767266]
CWR22R	IC₅₀	18.3 μM Compound: Curcumin	Cytotoxicity against human 22Rv1 cells after 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells after 72 hrs by MTT assay	[PMID: 19725582]
DLD-1	GI₅₀	8 μM Compound: curcumin	Cytotoxicity against human DLD1 cells Cytotoxicity against human DLD1 cells	[PMID: 20060305]
DLD-1	IC₅₀	>40 μM Compound: CUR	Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
DLD-1	IC₅₀	10 μM Compound: Cur	Synergistic antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth Synergistic antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth	[PMID: 33310285]
DLD-1	IC₅₀	145.5 μM Compound: CU	Cytotoxicity against human DLD1 cells Cytotoxicity against human DLD1 cells	[PMID: 31336310]
DU-145	IC₅₀	0.3 μM Compound: 1, Curcumin	Cytotoxicity against human DU145 cells after 5 days by trypan blue exclusion assay Cytotoxicity against human DU145 cells after 5 days by trypan blue exclusion assay	[PMID: 24531225]
DU-145	IC₅₀	2 μM Compound: 1	Antiproliferative activity against androgen-insensitive human DU145 cells Antiproliferative activity against androgen-insensitive human DU145 cells	[PMID: 30121214]
DU-145	IC₅₀	20.6 μM Compound: curcumin	Cytotoxicity against human DU145 Cytotoxicity against human DU145	[PMID: 16038556]
DU-145	IC₅₀	26.2 μM Compound: Curcumin	Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
DU-145	IC₅₀	26.23 μM Compound: 1	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 28388523]
DU-145	IC₅₀	26.23 μM Compound: 1	Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 30121214]
DU-145	IC₅₀	26.23 μM Compound: 1a; Curcumin	Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
DU-145	IC₅₀	26.23 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay	[PMID: 27543391]
DU-145	IC₅₀	26.23 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
DU-145	IC₅₀	26.23 μM Compound: curcumin	Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation after 3 days by WST1 assay Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation after 3 days by WST1 assay	[PMID: 25961334]
DU-145	IC₅₀	28.41 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 28038323]
DU-145	IC₅₀	31.7 μM Compound: 1; CUR	Anticancer activity against human DU145 cells Anticancer activity against human DU145 cells	[PMID: 31129455]
DU-145	IC₅₀	33.12 μM Compound: Curcumin	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
DU-145	IC₅₀	33.15 μM Compound: Curcumin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29429834]
DU-145	IC₅₀	38.17 μM Compound: 8	Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay	[PMID: 22546674]
DU-145	IC₅₀	41 μM Compound: Curcumin	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
DU-145	IC₅₀	44.71 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27816267]
EA.hy 926	IC₅₀	>25 μM Compound: 1a	Growth inhibition of human EAhy926 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of human EAhy926 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
EA.hy 926	IC₅₀	>25 μM Compound: 1a	Growth inhibition of human EAhy926 cells measured after 72 hrs by SRB assay Growth inhibition of human EAhy926 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
EA.hy 926	IC₅₀	20 μM Compound: 1; CUR	Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay	[PMID: 31129455]
EA.hy 926	IC₅₀	24.6 μM Compound: 1a	Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
Ehrlich	ED₅₀	100 mM Compound: 1	Cytotoxicity against Mus musculus (mouse) EAC assessed as cell viability by trypan blue exclusion assay Cytotoxicity against Mus musculus (mouse) EAC assessed as cell viability by trypan blue exclusion assay	10.1007/s00044-009-9199-3
EOL1	IC₅₀	6.7 μM Compound: 2	Cytotoxicity against human EOL-1 cells after 48 hrs by MTT assay Cytotoxicity against human EOL-1 cells after 48 hrs by MTT assay	[PMID: 24689857]
GES1	IC₅₀	27.89 μM Compound: CUR	Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
GES1	IC₅₀	29.1 μM Compound: 1; CUR	Cytotoxicity against human GES-1 cells Cytotoxicity against human GES-1 cells	[PMID: 31129455]
HaCaT	IC₅₀	13 μM Compound: CU	Cytotoxicity against human HaCaT cells Cytotoxicity against human HaCaT cells	[PMID: 31336310]
HaCaT	IC₅₀	21.9 μM Compound: 1	Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay	[PMID: 20831222]
HaCaT	IC₅₀	33.9 μM Compound: 1	Inhibition of STAT3 transcriptional activity in human HaCaT cells after 6 hrs by luciferase reporter gene assay Inhibition of STAT3 transcriptional activity in human HaCaT cells after 6 hrs by luciferase reporter gene assay	[PMID: 24920381]
HCT-116	EC₅₀	20 μM Compound: 1, CM	Agonist activity at human VDR expressed in human HCT116 cells co-expressing VDRE assessed as XDR3 transcriptional activity after 24 hrs by luciferase reporter gene assay Agonist activity at human VDR expressed in human HCT116 cells co-expressing VDRE assessed as XDR3 transcriptional activity after 24 hrs by luciferase reporter gene assay	[PMID: 23276449]
HCT-116	GI₅₀	3.5 μM Compound: 5	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 28716495]
HCT-116	IC₅₀	>=5.51 μM Compound: 1; CUR	Cytotoxicity against human HCT116 Cells Cytotoxicity against human HCT116 Cells	[PMID: 31129455]
HCT-116	IC₅₀	10 μM Compound: Curcumin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr	[PMID: 30776692]
HCT-116	IC₅₀	10 μM Compound: Cur	Synergistic antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth Synergistic antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth	[PMID: 33310285]
HCT-116	IC₅₀	10 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay	10.1007/s00044-011-9851-6
HCT-116	IC₅₀	10.5 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31326241]
HCT-116	IC₅₀	10.91 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29886021]
HCT-116	IC₅₀	11.54 μM Compound: Curcumin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 23644215]
HCT-116	IC₅₀	13 μM Compound: Curcumin, CURC	Cytotoxicity against human HCT116 cells after 24 hrs by crystal violet dye assay Cytotoxicity against human HCT116 cells after 24 hrs by crystal violet dye assay	[PMID: 22029378]
HCT-116	IC₅₀	13.77 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay	[PMID: 28319780]
HCT-116	IC₅₀	2.4 μM Compound: 3	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 32273215]
HCT-116	IC₅₀	2.67 μM Compound: 3	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 32273215]
HCT-116	IC₅₀	3.83 μM Compound: 3	Antiproliferative activity against human HCT116 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 24 hrs by MTT assay	[PMID: 32273215]
HCT-116	IC₅₀	34.7 μM Compound: Curcumin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32731188]
HCT-116	IC₅₀	4 μM Compound: Curcumin, CURC	Cytotoxicity against human HCT116 cells after 48 hrs by crystal violet dye assay Cytotoxicity against human HCT116 cells after 48 hrs by crystal violet dye assay	[PMID: 22029378]
HCT-116	IC₅₀	41.5 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23357628]
HCT-116	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
HCT-116	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
HCT-116	IC₅₀	50 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells after 36 hrs by XTT assay Antiproliferative activity against human HCT116 cells after 36 hrs by XTT assay	[PMID: 29886021]
HCT-116	IC₅₀	50 mM Compound: 3, Curcumin, diferulolylmethane	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22440624]
HCT-116	IC₅₀	50 mM Compound: Curcumin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 23685942]
HCT-8	IC₅₀	6.278 μg/mL Compound: Curcumin	Antiproliferative activity against human HCT8 cells Antiproliferative activity against human HCT8 cells	[PMID: 29432947]
HEK293	CC₅₀	5.56 μM Compound: 1	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis	[PMID: 36608774]
HEK293	EC₅₀	20.7 μM Compound: 1a, curcumin	Inhibition of Wnt3A/beta-catenin signaling in HEK293 cells after 24 hrs by firefly/renilla dual luciferase reporter gene assay Inhibition of Wnt3A/beta-catenin signaling in HEK293 cells after 24 hrs by firefly/renilla dual luciferase reporter gene assay	[PMID: 24275249]
HEK293	EC₅₀	37 μM Compound: 1	Cytotoxicity against HEK293 cells after 16 hrs by alamar blue assay Cytotoxicity against HEK293 cells after 16 hrs by alamar blue assay	[PMID: 20004045]
HEK293	IC₅₀	>400 μM Compound: Curcumin	Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 26783179]
HEK293	IC₅₀	7.7 μg/mL Compound: Curc	Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells preincubated for 16 hrs followed by TNFalpha addition and measured after 6 hrs by luminescence based assay Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells preincubated for 16 hrs followed by TNFalpha addition and measured after 6 hrs by luminescence based assay	[PMID: 31767266]
HEK293	IC₅₀	7.7 μg/mL Compound: 1, Curcumin	Inhibition of TNFalpha-induced nuclear factor-kappa-B (unknown origin) expressed in HEK293 cells pre-incubated for 16 hrs followed by TNFalpha stimulation for 6 hrs by luciferase reporter gene assay Inhibition of TNFalpha-induced nuclear factor-kappa-B (unknown origin) expressed in HEK293 cells pre-incubated for 16 hrs followed by TNFalpha stimulation for 6 hrs by luciferase reporter gene assay	[PMID: 25881826]
HEK293	IC₅₀	94.1 μM Compound: Curcumin	Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
HEK-293T	IC₅₀	>400 μM Compound: Curcumin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28797797]
HEK-293T	IC₅₀	15.2 μM Compound: 23	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	10.1039/C5MD00481K
HEL	CC₅₀	>0.002 μM Compound: Curcumin	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>0.002 μM Compound: Curcumin	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>0.002 μM Compound: Curcumin	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>0.002 μM Compound: Curcumin	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>=0.01 μM Compound: Curcumin	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.01 μM Compound: Curcumin	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.01 μM Compound: Curcumin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.01 μM Compound: Curcumin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.01 μM Compound: Curcumin	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HeLa	CC₅₀	>=0.01 μM Compound: Curcumin	Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method	[PMID: 20034711]
HeLa	CC₅₀	>=0.01 μM Compound: Curcumin	Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method	[PMID: 20034711]
HeLa	CC₅₀	>=0.01 μM Compound: Curcumin	Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method	[PMID: 20034711]
HeLa	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay	[PMID: 20034711]
HeLa	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20034711]
HeLa	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HeLa	IC₅₀	10.46 μM Compound: curcumin	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 3 days by trypan blue dye exclusion assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 3 days by trypan blue dye exclusion assay	[PMID: 25961334]
HeLa	IC₅₀	115 μM Compound: 28, diferuloylmethane	Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay	[PMID: 19520580]
HeLa	IC₅₀	12.11 μM Compound: 1a; Curcumin	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
HeLa	IC₅₀	12.11 μM Compound: curcumin	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation after 3 days by WST1 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation after 3 days by WST1 assay	[PMID: 25961334]
HeLa	IC₅₀	12.6 μM Compound: 1, Curcumin	Cytotoxicity against human HeLa cells after 5 days by trypan blue exclusion assay Cytotoxicity against human HeLa cells after 5 days by trypan blue exclusion assay	[PMID: 24531225]
HeLa	IC₅₀	13.8 μM Compound: 6	Antiproliferative activity against Homo sapiens (human) HeLa cells Antiproliferative activity against Homo sapiens (human) HeLa cells	10.1007/s00044-010-9344-z
HeLa	IC₅₀	14.03 μM Compound: 1; CUR	Cytotoxicity against human HeLa Cells Cytotoxicity against human HeLa Cells	[PMID: 31129455]
HeLa	IC₅₀	17 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay	10.1007/s00044-011-9851-6
HeLa	IC₅₀	17 μM Compound: Curcumin	Anticancer activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability after 72 hr by MTT assay	10.1007/s00044-013-0510-y
HeLa	IC₅₀	17.31 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) HeLa cell by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cell by MTT assay	10.1007/s00044-010-9353-y
HeLa	IC₅₀	17.5 μM Compound: Cur, (Curcumin)	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19243951]
HeLa	IC₅₀	18 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as loss of cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as loss of cell viability after 48 hrs by MTT assay	[PMID: 21830815]
HeLa	IC₅₀	18 μM Compound: Curcumin	Cytostatic activity against human HeLa cells Cytostatic activity against human HeLa cells	[PMID: 25577711]
HeLa	IC₅₀	187 μM Compound: 4	Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay	[PMID: 26588603]
HeLa	IC₅₀	21.2 μM Compound: Curcumin	Antiproliferative activity against human HeLa cells after 72 hrs by coulter counting analysis Antiproliferative activity against human HeLa cells after 72 hrs by coulter counting analysis	[PMID: 24657568]
HeLa	IC₅₀	21.8 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs	[PMID: 26705144]
HeLa	IC₅₀	25.41 μM Compound: Curcumin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28038323]
HeLa	IC₅₀	25.41 μM Compound: Curcumin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38107170]
HeLa	IC₅₀	27.4 μM Compound: Curcumin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21215629]
HeLa	IC₅₀	3.56 μM Compound: 3	Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 32273215]
HeLa	IC₅₀	3.57 μM Compound: 3	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 32273215]
HeLa	IC₅₀	31.89 μM Compound: Curcumin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HeLa	IC₅₀	32.4 μM Compound: 9	Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay	[PMID: 34669417]
HeLa	IC₅₀	4.33 μM Compound: 1; CUR	Anticancer activity against human HeLa cells Anticancer activity against human HeLa cells	[PMID: 31129455]
HeLa	IC₅₀	5.39 μM Compound: 3	Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay	[PMID: 32273215]
HeLa	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
HeLa	IC₅₀	50 mM Compound: Curcumin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 23685942]
HeLa	IC₅₀	51.87 μM Compound: Curcumin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 26873414]
HeLa	IC₅₀	8.2 μM Compound: CU	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 31336310]
Hep 3B2	IC₅₀	10 μM Compound: CU	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 31336310]
HEp-2	IC₅₀	21.37 μM Compound: 1; CUR	Cytotoxicity against human Hep2 Cells Cytotoxicity against human Hep2 Cells	[PMID: 31129455]
HEp-2	IC₅₀	56.9 μM Compound: Curcumin	Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay	[PMID: 21215629]
HepG2	IC₅₀	10 μM Compound: Curcumin-I	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29798827]
HepG2	IC₅₀	13.78 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HepG2	IC₅₀	16 μM Compound: Curcumin	Anticancer activity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell viability after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell viability after 72 hr by MTT assay	10.1007/s00044-013-0510-y
HepG2	IC₅₀	16.01 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
HepG2	IC₅₀	17.3 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
HepG2	IC₅₀	17.37 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
HepG2	IC₅₀	19.25 μM Compound: Curcumin	Inhibition of STAT3 in IL-6-stimulated human HepG2 cells treated for 1 hr prior to IL-6 challenge measured after 5.5 hrs by luciferase reporter gene assay Inhibition of STAT3 in IL-6-stimulated human HepG2 cells treated for 1 hr prior to IL-6 challenge measured after 5.5 hrs by luciferase reporter gene assay	[PMID: 23376248]
HepG2	IC₅₀	19.25 μM Compound: Curcumin	Inhibition of IL-6-induced STAT3 pathway in human HepG2 cells by luciferase reporter gene assay Inhibition of IL-6-induced STAT3 pathway in human HepG2 cells by luciferase reporter gene assay	[PMID: 23434226]
HepG2	IC₅₀	20.3 μM Compound: 1; CUR	Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay	[PMID: 31129455]
HepG2	IC₅₀	20.69 μM Compound: Curcumin	Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 22889562]
HepG2	IC₅₀	22.75 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
HepG2	IC₅₀	26.99 μM Compound: Curcumin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23245570]
HepG2	IC₅₀	27.23 μM Compound: 4	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
HepG2	IC₅₀	31.3 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells after 72 hrs by crystal violet staining based microplate reader analysis Cytotoxicity against human HepG2 cells after 72 hrs by crystal violet staining based microplate reader analysis	[PMID: 23153397]
HepG2	IC₅₀	31.6 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21215629]
HepG2	IC₅₀	35.53 μM Compound: curcumin	Cytotoxicity against human HepG2 Cytotoxicity against human HepG2	[PMID: 16038556]
HepG2	IC₅₀	36.77 μM Compound: 1; CUR	Cytotoxicity against human HepG2 Cells Cytotoxicity against human HepG2 Cells	[PMID: 31129455]
HepG2	IC₅₀	4.43 μM Compound: Curcumin	Cytotoxicity activity against human HepG2 cells by MTT assay Cytotoxicity activity against human HepG2 cells by MTT assay	[PMID: 26873414]
HepG2	IC₅₀	43.8 μM Compound: curcumin	Cytotoxicity against human HepG2 cells after 24 hrs by ATPLite assay Cytotoxicity against human HepG2 cells after 24 hrs by ATPLite assay	[PMID: 20297825]
HepG2	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
HepG2	IC₅₀	50 mM Compound: 3, Curcumin, diferulolylmethane	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22440624]
HepG2	IC₅₀	50 mM Compound: Curcumin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23685942]
HepG2	IC₅₀	52.3 μM Compound: curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26894841]
HepG2	IC₅₀	59.37 μM Compound: 8	Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay	[PMID: 22546674]
HepG2	IC₅₀	72.7 μM Compound: 1a	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
HepG2	IC₅₀	78.7 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23357628]
HepG2	IC₅₀	87.5 μM Compound: 1, Curcumin	Cytotoxicity against human HepG2 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
HepG2	IC₅₀	9.44 μM Compound: 1; CUR	Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay	[PMID: 31129455]
HL-60	IC₅₀	34.22 μM Compound: curcumin	Cytotoxicity against human HL60 Cytotoxicity against human HL60	[PMID: 16038556]
HL-60	IC₅₀	35.9 μM Compound: Cur, (Curcumin)	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19243951]
HL-60	IC₅₀	6.3 μM Compound: 1; CUR	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 31129455]
Hs 683	IC₅₀	22 μM Compound: 23, Curcumin	Anticancer activity against human Hs683 cells after 24 hrs by MTT assay Anticancer activity against human Hs683 cells after 24 hrs by MTT assay	[PMID: 20466556]
Hs-578T	IC₅₀	55.45 μM Compound: Curcumin	Antiproliferative activity against human Hs578T cells after 24 hrs by MTT assay Antiproliferative activity against human Hs578T cells after 24 hrs by MTT assay	[PMID: 28319780]
HSC-2	IC₅₀	3.1 μM Compound: Cur	Synergistic cytotoxicity against human HSC-2 cells Synergistic cytotoxicity against human HSC-2 cells	[PMID: 33310285]
HSC-2	IC₅₀	7.8 μM Compound: 1; CUR	Cytotoxicity against human HSC2 cells Cytotoxicity against human HSC2 cells	[PMID: 31129455]
HSC-3	IC₅₀	11 μM Compound: 1; CUR	Cytotoxicity against human HSC3 cells Cytotoxicity against human HSC3 cells	[PMID: 31129455]
HSC-4	IC₅₀	7.1 μM Compound: 1; CUR	Cytotoxicity against human HSC4 cells Cytotoxicity against human HSC4 cells	[PMID: 31129455]
HT-1080	ED₅₀	23.4 μM Compound: curcumin	Cytotoxicity against human HT1080 cells by MTT assay Cytotoxicity against human HT1080 cells by MTT assay	[PMID: 11430002]
HT-1080	IC₅₀	10 μM Compound: CU	Decrease in UPA expression in human HT1080 cells Decrease in UPA expression in human HT1080 cells	[PMID: 31336310]
HT-1080	IC₅₀	13.1 μM Compound: Curcumin	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 30138803]
HT-1080	IC₅₀	21.92 μM Compound: Curcumin	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
HT-22	IC₅₀	20.4 μM Compound: 1	Antiproliferative activity against mouse HT22 cells after 72 hrs by MTT assay Antiproliferative activity against mouse HT22 cells after 72 hrs by MTT assay	[PMID: 20831222]
HT-22	IC₅₀	52.4 μM Compound: 38	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	>25 μM Compound: 1a	Growth inhibition of human HT-29 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of human HT-29 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
HT-29	IC₅₀	>25 μM Compound: 1a	Growth inhibition of human HT-29 cells measured after 72 hrs by SRB assay Growth inhibition of human HT-29 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
HT-29	IC₅₀	13.2 μM Compound: Curcumin	Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 23644215]
HT-29	IC₅₀	132.37 μM Compound: CU	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 31336310]
HT-29	IC₅₀	14 μM Compound: Curc	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	15.9 μM Compound: 8	Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay	[PMID: 22546674]
HT-29	IC₅₀	18.74 μM Compound: 1; CUR	Cytotoxicity against human HT-29 Cells Cytotoxicity against human HT-29 Cells	[PMID: 31129455]
HT-29	IC₅₀	18.74 μM Compound: Curcumin	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22551677]
HT-29	IC₅₀	20.73 μM Compound: CU	Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay	[PMID: 31336310]
HT-29	IC₅₀	23.4 μM Compound: 1; CUR	Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay	[PMID: 31129455]
HT-29	IC₅₀	51.7 μM Compound: 1a	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
Huh-7	IC₅₀	48 μM Compound: Curcumin	Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay	[PMID: 26783179]
HUVEC	IC₅₀	10.84 μg/mL Compound: Entry Curcumin	Inhibitory concentration against human umbilical vein endothelial cells(HUVEC) growth Inhibitory concentration against human umbilical vein endothelial cells(HUVEC) growth	[PMID: 15993583]
IMR-32	ED₅₀	23.9 μM Compound: 15	Effective dose to protect IMR-32 cells from beta-Amyloid (BA) insult was determined using MTT reduction assay Effective dose to protect IMR-32 cells from beta-Amyloid (BA) insult was determined using MTT reduction assay	[PMID: 14980683]
IMR-32	ED₅₀	7.4 μg/mL Compound: 32 (Curcumin)	Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards IMR-32 human neuroblastoma cell Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards IMR-32 human neuroblastoma cell	[PMID: 11549465]
J774.1	IC₅₀	31 μM Compound: 23	Cytotoxicity against mouse J774.1 cells Cytotoxicity against mouse J774.1 cells	10.1039/C5MD00481K
J774.A1	IC₅₀	18.52 μM Compound: Curcumin	Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
J774.A1	IC₅₀	18.52 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
J774.A1	IC₅₀	18.52 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse J774A.1 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse J774A.1 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 25824662]
J774.A1	IC₅₀	2.08 μg/mL Compound: Curcumin	Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
J774.A1	IC₅₀	24.82 μg/mL Compound: Curcumin	Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
J774.A1	IC₅₀	5.6 μM Compound: Curcumin	Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay	[PMID: 25824662]
J774.A1	IC₅₀	67.4 μM Compound: Curcumin	Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay	[PMID: 25824662]
Jurkat	IC₅₀	4.29 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 24280069]
K562	GI₅₀	19.67 μM Compound: 1	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	GI₅₀	21.67 μM Compound: 1	Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	IC₅₀	15 μM Compound: Curcumin	Inhibition of NF-kappaB activation in human K562 cells Inhibition of NF-kappaB activation in human K562 cells	[PMID: 20728364]
K562	IC₅₀	23.12 μM Compound: Curcumin	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
K562	IC₅₀	36 μM Compound: 1; CUR	Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay	[PMID: 31129455]
K562	IC₅₀	46.76 μM Compound: 4	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
K562	IC₅₀	49.2 μM Compound: 6	Cytotoxicity against Homo sapiens (human) K562 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells after 72 hr by MTT assay	10.1007/s00044-010-9344-z
K562	IC₅₀	54.3 μM Compound: 6	Cytotoxicity against Homo sapiens (human) K562 cells Cytotoxicity against Homo sapiens (human) K562 cells	10.1007/s00044-010-9344-z
K562	IC₅₀	6.81 μM Compound: curcumin	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	8 μM Compound: Curcumin	Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay	[PMID: 24775915]
KB	CC₅₀	16 μM Compound: 3	Compound concentration required to reduce the exponential growth of KB cells by 50% Compound concentration required to reduce the exponential growth of KB cells by 50%	[PMID: 9767632]
KB	IC₅₀	>25 μM Compound: 1, curcumin, Diferuloylmethane	Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining	10.1007/s00044-011-9587-3
KB	IC₅₀	11.6 μM Compound: Cur, (Curcumin)	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19243951]
KB	IC₅₀	21.36 μM Compound: 1	Cytotoxicity against human KB cells assessed as growth inhibition by resazurin microplate assay Cytotoxicity against human KB cells assessed as growth inhibition by resazurin microplate assay	[PMID: 24857542]
KB	IC₅₀	3.1 μg/mL Compound: 2	Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KB	IC₅₀	5.5 μg/mL Compound: 2	Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KBM5	IC₅₀	3.84 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay	[PMID: 24280069]
KM12	IC₅₀	16 μM Compound: CU	Cytotoxicity against human KM12 cells after 4 hrs by MTT assay Cytotoxicity against human KM12 cells after 4 hrs by MTT assay	[PMID: 31336310]
L02	IC₅₀	>100 μM Compound: H-CUR	Antiproliferative activity against human HL7702 cells assessed as inhibition of cell viability Antiproliferative activity against human HL7702 cells assessed as inhibition of cell viability	[PMID: 38665827]
L02	IC₅₀	22.69 μM Compound: Curcumin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
L02	IC₅₀	23.87 μM Compound: Curcumin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
L02	IC₅₀	25.67 μM Compound: Curcumin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
L02	IC₅₀	32.33 μM Compound: 1; CUR	Cytotoxicity against human HL-7702 cells Cytotoxicity against human HL-7702 cells	[PMID: 31129455]
L02	IC₅₀	7.2 μM Compound: Curcumin	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
L1210	IC₅₀	15.1 μM Compound: Curcumin	Antiproliferative activity against mouse L1210 cells after 72 hrs by coulter counting analysis Antiproliferative activity against mouse L1210 cells after 72 hrs by coulter counting analysis	[PMID: 24657568]
L1210	IC₅₀	22 μM Compound: Curcumin	Cytostatic activity against mouse L1210 cells Cytostatic activity against mouse L1210 cells	[PMID: 25577711]
L1210	IC₅₀	9 μM Compound: 1, curcumin	Cytostatic activity against mouse L1210 cells Cytostatic activity against mouse L1210 cells	[PMID: 17768050]
L929	IC₅₀	20 μM Compound: curcumin	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity by MTT assay relative to untreated control	[PMID: 19775895]
Lewis lung carcinoma cell line	IC₅₀	24.7 μM Compound: CUR	Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay	[PMID: 27886548]
LN-229	IC₅₀	15 μM Compound: Curc	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LNCaP	EC₅₀	35 μM Compound: 3, curcumin	Decrease in androgen receptor protein expression in LNCaP cells by Western blotting Decrease in androgen receptor protein expression in LNCaP cells by Western blotting	[PMID: 17383188]
LNCaP	EC₅₀	9.9 μM Compound: 1	Activation of Nrf2 transcriptional activity in human LNCaP cells after 6 hrs by luciferase reporter gene assay relative to tert-butylhydroquinone Activation of Nrf2 transcriptional activity in human LNCaP cells after 6 hrs by luciferase reporter gene assay relative to tert-butylhydroquinone	[PMID: 24920381]
LNCaP	IC₅₀	12.1 μM Compound: Curcumin	Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
LNCaP	IC₅₀	13.61 μM Compound: 1	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 28388523]
LNCaP	IC₅₀	13.61 μM Compound: 1	Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 30121214]
LNCaP	IC₅₀	13.61 μM Compound: 1a; Curcumin	Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
LNCaP	IC₅₀	13.61 μM Compound: Curcumin	Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay	[PMID: 27543391]
LNCaP	IC₅₀	13.61 μM Compound: Curcumin	Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
LNCaP	IC₅₀	13.61 μM Compound: curcumin	Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by WST1 assay Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by WST1 assay	[PMID: 25961334]
LNCaP	IC₅₀	19.6 μM Compound: curcumin	Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay	[PMID: 19249204]
LNCaP	IC₅₀	2 μM Compound: 1	Antiproliferative activity against androgen-sensitive human LNCAP cells Antiproliferative activity against androgen-sensitive human LNCAP cells	[PMID: 30121214]
LNCaP	IC₅₀	3.8 μM Compound: 1, Curcumin	Cytotoxicity against human LNCaP cell line Cytotoxicity against human LNCaP cell line	[PMID: 16789753]
LNCaP	IC₅₀	36 μM Compound: 1	Cytotoxicity against human LNCAP cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24920381]
LNCaP	IC₅₀	36.4 μM Compound: 1	Cytotoxicity against androgen-dependent human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against androgen-dependent human LNCAP cells after 72 hrs by SRB assay	[PMID: 22672984]
LNCaP	IC₅₀	8.5 μM Compound: Curcumin	Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay	[PMID: 19725582]
LNCaP C4-2B	IC₅₀	6.1 μM Compound: Curcumin	Cytotoxicity against human C4-2B cells after 72 hrs by MTT assay Cytotoxicity against human C4-2B cells after 72 hrs by MTT assay	[PMID: 19725582]
LoVo	GI₅₀	4.3 μg/mL Compound: Curc	Growth inhibition of human LoVo cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability Growth inhibition of human LoVo cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability	[PMID: 31767266]
LoVo	IC₅₀	10 μM Compound: Curcumin, CURC	Cytotoxicity against human LoVo cells after 48 hrs by crystal violet dye assay Cytotoxicity against human LoVo cells after 48 hrs by crystal violet dye assay	[PMID: 22029378]
LoVo	IC₅₀	16 μM Compound: Curcumin, CURC	Cytotoxicity against human LoVo cells after 24 hrs by crystal violet dye assay Cytotoxicity against human LoVo cells after 24 hrs by crystal violet dye assay	[PMID: 22029378]
LoVo	IC₅₀	24 μM Compound: 23, Curcumin	Anticancer activity against human LoVo cells after 24 hrs by MTT assay Anticancer activity against human LoVo cells after 24 hrs by MTT assay	[PMID: 20466556]
LS174T	IC₅₀	6.4 μM Compound: Cur, (Curcumin)	Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay	[PMID: 19243951]
LS174T	IC₅₀	6.5 μM Compound: CCMN, curcurmin	Cytotoxicity against human LS174T cells Cytotoxicity against human LS174T cells	[PMID: 17973470]
MCF-10A	IC₅₀	30.1 μM Compound: curcumin	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 19249204]
MCF7	GI₅₀	4.7 μM Compound: BML-EI135	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21514701]
MCF7	IC₅₀	10.44 μM Compound: curcumin	Cytotoxicity against human MCF7 Cytotoxicity against human MCF7	[PMID: 16038556]
MCF7	IC₅₀	12 μM Compound: 6	Antiproliferative activity against Homo sapiens (human) MCF7 cells Antiproliferative activity against Homo sapiens (human) MCF7 cells	10.1007/s00044-010-9344-z
MCF7	IC₅₀	13.7 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32731188]
MCF7	IC₅₀	15.66 μM Compound: Curcumin	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22889562]
MCF7	IC₅₀	17.1 μM Compound: 1; CUR	Induction of apoptosis in human MCF7 cells Induction of apoptosis in human MCF7 cells	[PMID: 31129455]
MCF7	IC₅₀	19.9 μM Compound: CU	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 31336310]
MCF7	IC₅₀	2.03 μM Compound: 3	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32273215]
MCF7	IC₅₀	2.08 μM Compound: 3	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 32273215]
MCF7	IC₅₀	2.94 μM Compound: 3	Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay	[PMID: 32273215]
MCF7	IC₅₀	21.39 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) MCF7 cell by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cell by MTT assay	10.1007/s00044-010-9353-y
MCF7	IC₅₀	21.5 μM Compound: curcumin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19249204]
MCF7	IC₅₀	22.1 μM Compound: CUR	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
MCF7	IC₅₀	22.5 μM Compound: 1; CUR	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 31129455]
MCF7	IC₅₀	24 μM Compound: 23, Curcumin	Anticancer activity against human MCF7 cells after 24 hrs by MTT assay Anticancer activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20466556]
MCF7	IC₅₀	24.46 μM Compound: curcumin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20805034]
MCF7	IC₅₀	26 μM Compound: Curcumin	Anticancer activity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell viability after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell viability after 72 hr by MTT assay	10.1007/s00044-013-0510-y
MCF7	IC₅₀	29.3 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay	[PMID: 34000484]
MCF7	IC₅₀	29.3 μM Compound: 1, curcumin	Growth inhibition of human MCF7 cells after 48 hrs by MTS assay Growth inhibition of human MCF7 cells after 48 hrs by MTS assay	[PMID: 18039573]
MCF7	IC₅₀	29.3 μM Compound: Curcumin	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 28605676]
MCF7	IC₅₀	32.2 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 26174555]
MCF7	IC₅₀	41.9 μM Compound: 50	Anticancer activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay Anticancer activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36332549]
MCF7	IC₅₀	42.89 μM Compound: Curcumin	Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 28319780]
MCF7	IC₅₀	46.25 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 26873414]
MCF7	IC₅₀	48 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21215629]
MCF7	IC₅₀	49.8 μM Compound: 1, Curcumin	Cytotoxicity against human MCF7 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
MCF7	IC₅₀	5.58 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS-PMS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS-PMS assay	[PMID: 19019687]
MCF7	IC₅₀	51.5 μM Compound: curcumin	Cytotoxicity against human MCF7 cells after 24 hrs by ATPLite assay Cytotoxicity against human MCF7 cells after 24 hrs by ATPLite assay	[PMID: 20297825]
MCF7	IC₅₀	61.71 μM Compound: Curcumin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of resveratrol by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of resveratrol by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	65.16 μM Compound: 8	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 22546674]
MCF7	IC₅₀	68.25 μM Compound: 1; CUR	Cytotoxicity against human MCF7 Cells after 48 hrs by MTS assay Cytotoxicity against human MCF7 Cells after 48 hrs by MTS assay	[PMID: 31129455]
MCF7	IC₅₀	68.25 μM Compound: Curcumin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	70.2 μM Compound: CUR	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25728027]
MCF7	IC₅₀	83.1 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
MCF7	IC₅₀	83.1 μM Compound: Curcumin	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 38889607]
MCF7	IC₅₀	88 nM Compound: 3	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth in presence of paclitaxel by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth in presence of paclitaxel by MTT assay	[PMID: 37847948]
MCF7	IC₅₀	9.28 μM Compound: 1; CUR	Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay	[PMID: 31129455]
MCF7	IC₅₀	9.8 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30138803]
MCF7R	IC₅₀	26.2 μM Compound: Curcumin	Cytotoxicity against human MCF7R cells assessed as cell growth inhibition and by MTT assay Cytotoxicity against human MCF7R cells assessed as cell growth inhibition and by MTT assay	[PMID: 34000484]
MCF7R	IC₅₀	26.2 μM Compound: 1, curcumin	Growth inhibition of human multidrug-resistant MCF7R cells after 48 hrs by MTS assay Growth inhibition of human multidrug-resistant MCF7R cells after 48 hrs by MTS assay	[PMID: 18039573]
MCF7R	IC₅₀	26.2 μM Compound: Curcumin	Antiproliferative activity against human MCF7R cells Antiproliferative activity against human MCF7R cells	[PMID: 28605676]
MDA-MB-157	IC₅₀	40.38 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDA-MB-231	EC₅₀	7.6 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 20728364]
MDA-MB-231	IC₅₀	>10 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29886021]
MDA-MB-231	IC₅₀	>20 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 38746900]
MDA-MB-231	IC₅₀	0.88 μM Compound: 1, Curcumin	Cytotoxicity against human MDA-MB-231 cells after 5 days by trypan blue exclusion assay Cytotoxicity against human MDA-MB-231 cells after 5 days by trypan blue exclusion assay	[PMID: 24531225]
MDA-MB-231	IC₅₀	11.45 μM Compound: 1; CUR	Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 31129455]
MDA-MB-231	IC₅₀	12 μM Compound: Curc	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	15 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 26561365]
MDA-MB-231	IC₅₀	15.81 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28038323]
MDA-MB-231	IC₅₀	16.23 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay	[PMID: 28319780]
MDA-MB-231	IC₅₀	24 μM Compound: Curcumin	Inhibition of TGF-beta-induced PTHrP secretion in human MDA-MB-231 cells treated 4 hrs before TGF-beta challenge measured after 24 hrs by radioimmunoassay Inhibition of TGF-beta-induced PTHrP secretion in human MDA-MB-231 cells treated 4 hrs before TGF-beta challenge measured after 24 hrs by radioimmunoassay	[PMID: 23145932]
MDA-MB-231	IC₅₀	24.54 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27816267]
MDA-MB-231	IC₅₀	25.6 μM Compound: curcumin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19249204]
MDA-MB-231	IC₅₀	26.5 μM Compound: 1; CUR	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 31129455]
MDA-MB-231	IC₅₀	31.39 μM Compound: 4	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
MDA-MB-231	IC₅₀	34.4 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay	[PMID: 25453798]
MDA-MB-231	IC₅₀	37.8 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining based microplate reader analysis Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining based microplate reader analysis	[PMID: 23153397]
MDA-MB-231	IC₅₀	53.51 μM Compound: 50	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36332549]
MDA-MB-231	IC₅₀	64.67 μM Compound: 8	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay	[PMID: 22546674]
MDA-MB-231	IC₅₀	75.3 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
MDA-MB-453	IC₅₀	32.4 μM Compound: Curcumin	Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDA-MB-468	EC₅₀	9.7 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-468 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 20728364]
MDA-MB-468	IC₅₀	196.5 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-468 cells harboring constitutively harboring activated STAT3 assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells harboring constitutively harboring activated STAT3 assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 23376248]
MDA-MB-468	IC₅₀	196.5 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell viability Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell viability	[PMID: 23434226]
MDA-MB-468	IC₅₀	42.89 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDA-MB-468	IC₅₀	58.55 μM Compound: Curcumin	Antiproliferative activity against doxorubicin-resistant human MDA-MB-468 cells after 24 hrs by MTT assay Antiproliferative activity against doxorubicin-resistant human MDA-MB-468 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDCK	CC₅₀	>0.092 μM Compound: Curcumin	Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method	[PMID: 20034711]
MDCK	CC₅₀	>0.092 μM Compound: Curcumin	Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method	[PMID: 20034711]
MDCK	CC₅₀	>0.092 μM Compound: Curcumin	Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method	[PMID: 20034711]
MDCK	CC₅₀	48.3 μM Compound: Curcumin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay	[PMID: 30108865]
MDCK	CC₅₀	48.3 μM Compound: Curcumin	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay	10.1039/C6MD00292G
MDCK	EC₅₀	>0.271 μM Compound: Curcumin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
MDCK	EC₅₀	>0.271 μM Compound: Curcumin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
MDCK	EC₅₀	>0.271 μM Compound: Curcumin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
MeWo	IC₅₀	35.5 μM Compound: 1a	Cytotoxicity against human MeWo cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MeWo cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23830698]
MGC-803	IC₅₀	>20 μM Compound: 1; CUR	Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay	[PMID: 31129455]
MGC-803	IC₅₀	21.2 μM Compound: 1; CUR	Cytotoxicity against human MGC803 cells Cytotoxicity against human MGC803 cells	[PMID: 31129455]
MGC-803	IC₅₀	31.39 μM Compound: CUR	Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
MIA PaCa-2	IC₅₀	20 μM Compound: 2	Cytotoxicity against human MIAPaCa2 cells by MTT assay Cytotoxicity against human MIAPaCa2 cells by MTT assay	[PMID: 26561365]
MIA PaCa-2	IC₅₀	9 μM Compound: CCMN, curcurmin	Cytotoxicity against human MIA PaCa2 cells Cytotoxicity against human MIA PaCa2 cells	[PMID: 17973470]
MOLT-4	IC₅₀	6.46 μM Compound: Curcumin	Antiproliferative activity against human Molt4/C8 cells after 72 hrs by coulter counting analysis Antiproliferative activity against human Molt4/C8 cells after 72 hrs by coulter counting analysis	[PMID: 24657568]
MOLT-4	IC₅₀	9 μM Compound: 1, curcumin	Cytostatic activity against human Molt4C/8 cells Cytostatic activity against human Molt4C/8 cells	[PMID: 17768050]
Monocyte	IC₅₀	1.2 μM Compound: 1	Inhibition of 11-HETE formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis Inhibition of 11-HETE formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis	[PMID: 24920381]
Monocyte	IC₅₀	1.2 μM Compound: 1	Inhibition of thromboxane B2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis Inhibition of thromboxane B2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis	[PMID: 24920381]
MRC5	IC₅₀	51.23 μM Compound: Curcumin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
MT4	CC₅₀	>0.037 μM Compound: Curcumin	Cytotoxicity against HIV1 3B-infected human MT4 cells by MTT assay Cytotoxicity against HIV1 3B-infected human MT4 cells by MTT assay	[PMID: 20034711]
MT4	CC₅₀	>0.037 μM Compound: Curcumin	Cytotoxicity against HIV2 ROD infected human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected human MT4 cells by MTT assay	[PMID: 20034711]
MT4	CC₅₀	7.4 μM Compound: 3	Compound concentration required to reduce the exponential growth of MT-4 cells by 50% Compound concentration required to reduce the exponential growth of MT-4 cells by 50%	[PMID: 9767632]
MT4	IC₅₀	0.037 μM Compound: Curcumin	Antiviral activity against HIV1 3B-infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B-infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 20034711]
MT4	IC₅₀	0.037 μM Compound: Curcumin	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 20034711]
N2a	IC₅₀	22.6 μM Compound: Curcumin	Neurotoxicity in mouse N2a cells assessed as cell viability for 24 hrs by MTT assay Neurotoxicity in mouse N2a cells assessed as cell viability for 24 hrs by MTT assay	[PMID: 34391121]
N9	IC₅₀	13.5 μM Compound: curcumin	Antiinflammatory activity against mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 48 hrs by Griess reaction relative to control Antiinflammatory activity against mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 48 hrs by Griess reaction relative to control	[PMID: 19691309]
NB-4	IC₅₀	6.01 μM Compound: Curcumin	Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24960549]
NCI-H1299	IC₅₀	18.93 μM Compound: 1; CUR	Cytotoxicity against human H1299 cells Cytotoxicity against human H1299 cells	[PMID: 31129455]
NCI-H157	GI₅₀	19.25 μM Compound: 1, Curcumin	Growth inhibition of human NCI-H157 cells after 72 hrs by alamar blue method Growth inhibition of human NCI-H157 cells after 72 hrs by alamar blue method	[PMID: 21070043]
NCI-H1650	IC₅₀	20.5 μM Compound: Curcumin	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H1650	IC₅₀	20.7 μM Compound: CUR	Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
NCI-H1944	GI₅₀	16.16 μM Compound: 1, Curcumin	Growth inhibition of human NCI-H1944 cells after 72 hrs by alamar blue method Growth inhibition of human NCI-H1944 cells after 72 hrs by alamar blue method	[PMID: 21070043]
NCI-H1975	IC₅₀	1.4 μM Compound: Curcumin	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H460	GI₅₀	12.13 μM Compound: 1, Curcumin	Growth inhibition of human H460 cells after 72 hrs by alamar blue method Growth inhibition of human H460 cells after 72 hrs by alamar blue method	[PMID: 21070043]
NCI-H460	GI₅₀	16.7 μM Compound: BML-EI135	Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 21514701]
NCI-H460	GI₅₀	27.3 μM Compound: 1	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27908756]
NCI-H460	IC₅₀	15 μM Compound: Curc	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NCI-H460	IC₅₀	17.11 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29429834]
NCI-H460	IC₅₀	17.14 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
NCI-H460	IC₅₀	20.29 μM Compound: Cur, Curcumin	Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 21504179]
NCI-H460	IC₅₀	20.3 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
NCI-H460	IC₅₀	20.34 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
NCI-H460	IC₅₀	27.6 μM Compound: curcumin	Cytotoxicity against human NCI-H460 Cytotoxicity against human NCI-H460	[PMID: 16038556]
NCI-H460	IC₅₀	5.3 μM Compound: 22	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 32172081]
NCI-H460	IC₅₀	51.3 μM Compound: 1, Curcumin	Cytotoxicity against human H460 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human H460 cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
NCI-H460	IC₅₀	8.5 μM Compound: Curcumin	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H460	IC₅₀	82.5 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human H460 cells after 24 hrs by MTT assay Cytotoxicity against human H460 cells after 24 hrs by MTT assay	[PMID: 26174555]
NHDF	IC₅₀	24.1 μM Compound: Curcumin	Cytotoxicity against NHDF after 72 hrs by MTT assay Cytotoxicity against NHDF after 72 hrs by MTT assay	[PMID: 30138803]
NIH3T3	IC₅₀	14.2 μM Compound: 1	Antiproliferative activity against BALB/c mouse 3T3 cells after 72 hrs by MTT assay Antiproliferative activity against BALB/c mouse 3T3 cells after 72 hrs by MTT assay	[PMID: 20831222]
NIH3T3	IC₅₀	9.51 μM Compound: 1; CUR	Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay	[PMID: 31129455]
NIH3T3	IC₅₀	9.6 μM Compound: curcumin	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
OE33	IC₅₀	35 μM Compound: 23, Curcumin	Anticancer activity against human OE33 cells after 24 hrs by MTT assay Anticancer activity against human OE33 cells after 24 hrs by MTT assay	[PMID: 20466556]
P388D1	IC₅₀	75.7 μM Compound: curcumin	Cytotoxicity against mouse P388D1 cells after 24 hrs by ATPLite assay Cytotoxicity against mouse P388D1 cells after 24 hrs by ATPLite assay	[PMID: 20297825]
PANC-1	IC₅₀	23.68 μM Compound: Curcumin	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 22551677]
PANC-1	IC₅₀	53 μM Compound: Curc	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PBMC	IC₅₀	12.3 μg/mL Compound: 1, Curcumin	Cytotoxicity against human PBMC after 3 days by MTT assay Cytotoxicity against human PBMC after 3 days by MTT assay	[PMID: 25881826]
PBMC	IC₅₀	2.71 μg/mL Compound: curcumin	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production treated for 30 mins followed by 5 hrs LPS challenge by ELISA assay Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production treated for 30 mins followed by 5 hrs LPS challenge by ELISA assay	[PMID: 21600765]
PBMC	IC₅₀	34.8 μM Compound: 1	Cytotoxicity against human PBMCs assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human PBMCs assessed as cell viability after 24 hrs by MTT assay	[PMID: 24920381]
PC-12	CC₅₀	42 μM Compound: 1; CUR	Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay	[PMID: 31262559]
PC-12	CC₅₀	44 μM Compound: Curcumin	Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay	[PMID: 33611188]
PC-12	CC₅₀	44 μM Compound: 1	Cytotoxicity against rat PC12 cells measured for 24 hrs by WST-assay Cytotoxicity against rat PC12 cells measured for 24 hrs by WST-assay	[PMID: 38740144]
PC-12	ED₅₀	10 μg/mL Compound: 3, curcumin	Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay	[PMID: 12350137]
PC-12	ED₅₀	17.1 μM Compound: 15	Effective dose to protect PC12 cells from beta-Amyloid (BA) insult was determined using MTT reduction assay Effective dose to protect PC12 cells from beta-Amyloid (BA) insult was determined using MTT reduction assay	[PMID: 14980683]
PC-12	ED₅₀	7 μg/mL Compound: 3, curcumin	Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay	[PMID: 12350137]
PC-12	ED₅₀	7.1 μg/mL Compound: 32 (Curcumin)	Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards PC12 rat pheochromocytoma cell Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards PC12 rat pheochromocytoma cell	[PMID: 11549465]
PC-3	GI₅₀	13.8 μg/mL Compound: Curc	Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay	[PMID: 31767266]
PC-3	IC₅₀	1.98 μM Compound: 1, Curcumin	Cytotoxicity against human PC3 cells after 5 days by trypan blue exclusion assay Cytotoxicity against human PC3 cells after 5 days by trypan blue exclusion assay	[PMID: 24531225]
PC-3	IC₅₀	12 μM Compound: CCMN, curcurmin	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17973470]
PC-3	IC₅₀	12.22 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28038323]
PC-3	IC₅₀	12.22 μM Compound: Curcumin	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth measured after 24 hrs by MTT assay	[PMID: 38107170]
PC-3	IC₅₀	12.36 μM Compound: curcumin	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 3 days by trypan blue dye exclusion assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 3 days by trypan blue dye exclusion assay	[PMID: 25961334]
PC-3	IC₅₀	15 μM Compound: Cur, (Curcumin)	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19243951]
PC-3	IC₅₀	16.8 μM Compound: Curcumin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19725582]
PC-3	IC₅₀	18.65 μM Compound: Curcumin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29429834]
PC-3	IC₅₀	18.71 μM Compound: Curcumin	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
PC-3	IC₅₀	18.8 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay	[PMID: 28319780]
PC-3	IC₅₀	19.37 μM Compound: Curcumin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22551677]
PC-3	IC₅₀	19.8 μM Compound: curcumin	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19249204]
PC-3	IC₅₀	19.98 μM Compound: 1; CUR	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 31129455]
PC-3	IC₅₀	2 μM Compound: 1	Antiproliferative activity against androgen-insensitive human PC3 cells Antiproliferative activity against androgen-insensitive human PC3 cells	[PMID: 30121214]
PC-3	IC₅₀	20.9 μM Compound: 1; CUR	Anticancer activity against human PC3 cells Anticancer activity against human PC3 cells	[PMID: 31129455]
PC-3	IC₅₀	22.7 μM Compound: curcumin	Cytotoxicity against human PC3 cells after 24 hrs by ATPLite assay Cytotoxicity against human PC3 cells after 24 hrs by ATPLite assay	[PMID: 20297825]
PC-3	IC₅₀	25.4 μM Compound: Curcumin	Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
PC-3	IC₅₀	25.43 μM Compound: 1	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 28388523]
PC-3	IC₅₀	25.43 μM Compound: 1	Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 30121214]
PC-3	IC₅₀	25.43 μM Compound: 1a; Curcumin	Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
PC-3	IC₅₀	25.43 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay	[PMID: 27543391]
PC-3	IC₅₀	25.43 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
PC-3	IC₅₀	25.43 μM Compound: curcumin	Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation after 3 days by WST1 assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation after 3 days by WST1 assay	[PMID: 25961334]
PC-3	IC₅₀	33 μM Compound: 23, Curcumin	Anticancer activity against human PC3 cells after 24 hrs by MTT assay Anticancer activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 20466556]
PC-3	IC₅₀	36 μM Compound: 1	Cytotoxicity against androgen-independent human PC3 cells after 72 hrs by SRB assay Cytotoxicity against androgen-independent human PC3 cells after 72 hrs by SRB assay	[PMID: 22672984]
PC-3	IC₅₀	39 μM Compound: Curcumin	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
PC-3	IC₅₀	39 μM Compound: Curcumin	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 38889607]
PC-3	IC₅₀	59.02 μM Compound: CUR	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25728027]
PC-3	IC₅₀	7.7 μM Compound: 1, Curcumin	Cytotoxicity against human PC3 cell line Cytotoxicity against human PC3 cell line	[PMID: 16789753]
PWR-1E	IC₅₀	8.14 μM Compound: 1	Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay	[PMID: 28388523]
PWR-1E	IC₅₀	8.85 μM Compound: Curcumin	Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
QG-56	IC₅₀	100 μM Compound: Curcumin	Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
QG-56	IC₅₀	100 μM Compound: Curcumin	Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
QG-56	IC₅₀	100 mM Compound: 3, Curcumin, diferulolylmethane	Cytotoxicity against human QG56 cells after 48 hrs by MTT assay Cytotoxicity against human QG56 cells after 48 hrs by MTT assay	[PMID: 22440624]
QG-56	IC₅₀	100 mM Compound: Curcumin	Cytotoxicity against human QG56 cells after 24 hrs by MTT assay Cytotoxicity against human QG56 cells after 24 hrs by MTT assay	[PMID: 23685942]
QGY-7703	IC₅₀	21.44 μM Compound: Curcumin	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
QGY-7703	IC₅₀	22.5 μM Compound: Curcumin	Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
QGY-7703	IC₅₀	23.91 μM Compound: Curcumin	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
Raji	IC₅₀	10.2 nM Compound: curcumin	Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs	[PMID: 17503850]
Raji	IC₅₀	331 μM Compound: 9	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48hrs by indirect immunofluorescence technique Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48hrs by indirect immunofluorescence technique	[PMID: 19131254]
Raji	IC₅₀	341 molar ratio Compound: Curcumin	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA	[PMID: 19481937]
Raji	IC₅₀	341 molar ratio Compound: Curcumin	Chemopreventive activity in human Raji cells assessed as molar ratio of compound required to inhibit 50% of control of inhibition of TPA-induced EBV-early antigen activation after 48 hrs by immunofluorescence analysis Chemopreventive activity in human Raji cells assessed as molar ratio of compound required to inhibit 50% of control of inhibition of TPA-induced EBV-early antigen activation after 48 hrs by immunofluorescence analysis	[PMID: 24411124]
Raji	IC₅₀	345 μM Compound: Curcumin	Inhibition of TPA-induced EBV-EA activation in Raji cells Inhibition of TPA-induced EBV-EA activation in Raji cells	[PMID: 17950604]
Raji	IC₅₀	345 μM Compound: curcumin	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique	[PMID: 19674905]
Raji	IC₅₀	97 molar ratio Compound: curcumin	Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA	[PMID: 26796952]
RAW264.7	IC₅₀	>100 μM Compound: Curcumin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	10.1039/C4MD00541D
RAW264.7	IC₅₀	0.8 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay	[PMID: 30108997]
RAW264.7	IC₅₀	0.8 μM Compound: Curcumin	Inhibition of iNOS induction in mouse RAW264.7 cells assessed as NO production Inhibition of iNOS induction in mouse RAW264.7 cells assessed as NO production	[PMID: 25058929]
RAW264.7	IC₅₀	1.25 μg/mL Compound: Curcumin	Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
RAW264.7	IC₅₀	1.89 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated with compound for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated with compound for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 35576655]
RAW264.7	IC₅₀	11.02 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
RAW264.7	IC₅₀	11.02 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
RAW264.7	IC₅₀	11.02 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 25824662]
RAW264.7	IC₅₀	11.2 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha level preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha level preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 33422907]
RAW264.7	IC₅₀	12.3 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess method	[PMID: 33422907]
RAW264.7	IC₅₀	14.7 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay	10.1039/C4MD00541D
RAW264.7	IC₅₀	14.7 μM Compound: Curcumin	Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse RAW264.7 cells incubated for 17 hrs by Griess assay Inhibition of nitric oxide production in LPS/IFNgamma-stimulated mouse RAW264.7 cells incubated for 17 hrs by Griess assay	[PMID: 26071636]
RAW264.7	IC₅₀	15.95 μM Compound: Curcumin	Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay	[PMID: 27040659]
RAW264.7	IC₅₀	17.5 μM Compound: Curcumin	Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay	[PMID: 25824662]
RAW264.7	IC₅₀	19.1 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 26841168]
RAW264.7	IC₅₀	2.2 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay	[PMID: 35029398]
RAW264.7	IC₅₀	20.38 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-stimulated nitric oxide production after 17 to 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-stimulated nitric oxide production after 17 to 20 hrs by Griess assay	[PMID: 19359068]
RAW264.7	IC₅₀	21.58 μM Compound: Curcumin	Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced nitric oxide production after 17 to 20 hr by Griess assay Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced nitric oxide production after 17 to 20 hr by Griess assay	10.1007/s00044-010-9521-0
RAW264.7	IC₅₀	22.5 μM Compound: Curcumin	Inhibition of NO production in LPS/IFNgamma-stimulated mouse RAW264.7 cells preincubated for 1 hr followed by LPS/IFNgamma addition and measured after 24 hrs by griess reagent based assay Inhibition of NO production in LPS/IFNgamma-stimulated mouse RAW264.7 cells preincubated for 1 hr followed by LPS/IFNgamma addition and measured after 24 hrs by griess reagent based assay	[PMID: 38964296]
RAW264.7	IC₅₀	22.91 μM Compound: curcumin	Inhibition of TPA-induced cell proliferation of mouse RAW264.7 cells Inhibition of TPA-induced cell proliferation of mouse RAW264.7 cells	[PMID: 26048786]
RAW264.7	IC₅₀	28.8 μM Compound: Curcumin	Cytotoxicity against LPS/IFNgamma-stimulated mouse RAW264.7 cells by MTT assay Cytotoxicity against LPS/IFNgamma-stimulated mouse RAW264.7 cells by MTT assay	[PMID: 26071636]
RAW264.7	IC₅₀	3 μM Compound: 1	Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs	[PMID: 30794412]
RAW264.7	IC₅₀	3.4 μM Compound: Curcumin	Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay	[PMID: 25824662]
RAW264.7	IC₅₀	3.5 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 34726063]
RAW264.7	IC₅₀	31.2 μM Compound: Curcumin	Inhibition of TNF-alpha production in LPS/IFNgamma-stimulated mouse RAW264.7 cells preincubated for 1 hr followed by LPS/IFNgamma addition and measured after 24 hrs by ELISA Inhibition of TNF-alpha production in LPS/IFNgamma-stimulated mouse RAW264.7 cells preincubated for 1 hr followed by LPS/IFNgamma addition and measured after 24 hrs by ELISA	[PMID: 38964296]
RAW264.7	IC₅₀	5 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS challenge measured after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS challenge measured after 24 hrs	[PMID: 24094143]
RAW264.7	IC₅₀	6 μM Compound: curcumin	Inhibition of TLR4 in LPS-stimulated mouse RAW264.7 cells assessed as reduction of NO production after 24 hrs Inhibition of TLR4 in LPS-stimulated mouse RAW264.7 cells assessed as reduction of NO production after 24 hrs	[PMID: 22985959]
RAW264.7	IC₅₀	6.2 μM Compound: Curcumin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated for 2 hrs before LPS stimulation for 24 hrs Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated for 2 hrs before LPS stimulation for 24 hrs	[PMID: 25453803]
RAW264.7	IC₅₀	6.44 μg/mL Compound: Curcumin	Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay	[PMID: 25113933]
RAW264.7	IC₅₀	8.3 μM Compound: curcumin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
RBL-2H3	IC₅₀	3 μM Compound: curcumin	Inhibition of rat RBL2H3 cell degranulation assessed as inhibition of beta-hexosamidase release after 10 mins by microplate reader assay Inhibition of rat RBL2H3 cell degranulation assessed as inhibition of beta-hexosamidase release after 10 mins by microplate reader assay	[PMID: 12398545]
RWPE-1	IC₅₀	15.62 μM Compound: 1; CUR	Cytotoxicity against human RWPE1 cells Cytotoxicity against human RWPE1 cells	[PMID: 31129455]
SAOS-2	EC₅₀	28.1 μM Compound: Curcumin	Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
SAOS-2	EC₅₀	48.6 μM Compound: Curcumin	Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
Sf21	IC₅₀	25 μM Compound: Curcumin	Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co	[PMID: 31910017]
SF-268	GI₅₀	5.1 μM Compound: BML-EI135	Antiproliferative activity against human SF268 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 21514701]
Sf9	IC₅₀	8.6 μM Compound: Curcumin	Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry	[PMID: 23245570]
SGC-7901	IC₅₀	>20 μM Compound: 1; CUR	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	[PMID: 31129455]
SGC-7901	IC₅₀	22.5 μM Compound: 1; CUR	Cytotoxicity against human SGC7901 cells Cytotoxicity against human SGC7901 cells	[PMID: 31129455]
SGC-7901	IC₅₀	24.41 μM Compound: CUR	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
SGC-7901	IC₅₀	26.2 μM Compound: Curcumin	Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
SGC-7901	IC₅₀	29 μM Compound: 1	Cytotoxicity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23357628]
SH-SY5Y	EC₅₀	5.29 μM Compound: Curcumin	Neuroprotective activity against 6-OHDA induced cell death in human SH-SY5Y cells preincubated with 6-hyrdoxydopamine followed by compound addition and measured after 24 hrs by MTT assay Neuroprotective activity against 6-OHDA induced cell death in human SH-SY5Y cells preincubated with 6-hyrdoxydopamine followed by compound addition and measured after 24 hrs by MTT assay	[PMID: 35968659]
SH-SY5Y	EC₅₀	6 μM Compound: curcumin	Neuroprotective activity against 6-hydroxydopamine-induced human SH-SY5Y cell death after 24 hrs by MTT assay Neuroprotective activity against 6-hydroxydopamine-induced human SH-SY5Y cell death after 24 hrs by MTT assay	[PMID: 25051453]
SH-SY5Y	EC₅₀	6.2 μM Compound: Curcumin	Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay	[PMID: 27420919]
SH-SY5Y	IC₅₀	105 μM Compound: 1, Curcumin	Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
SH-SY5Y	IC₅₀	11.4 μM Compound: 1a	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23830698]
SH-SY5Y	IC₅₀	12.8 μM Compound: 1	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 20831222]
SH-SY5Y	IC₅₀	16.1 μM Compound: 1	Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs	[PMID: 26705144]
SH-SY5Y	IC₅₀	35.6 μM Compound: Cur	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23501115]
SK-BR-3	IC₅₀	2.11 μM Compound: 1	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS-PMS assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS-PMS assay	[PMID: 19019687]
SK-BR-3	IC₅₀	2.4 μM Compound: Curcumin	Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay	[PMID: 20728364]
SK-BR-3	IC₅₀	27 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) SKBR3 cells by MTT assay Cytotoxicity against Homo sapiens (human) SKBR3 cells by MTT assay	10.1007/s00044-011-9851-6
SK-BR-3	IC₅₀	42.83 μM Compound: Curcumin	Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay	[PMID: 28319780]
SK-MEL	IC₅₀	13.75 μM Compound: 1, curcumin, Diferuloylmethane	Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining	10.1007/s00044-011-9587-3
SK-MEL-2	IC₅₀	36 μM Compound: Curc	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SK-MEL-5	IC₅₀	50.37 μM Compound: 8	Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay	[PMID: 22546674]
SK-N-FI	IC₅₀	11.3 μM Compound: Curcumin	Cytotoxicity against human SK-N-FI cells after 5 days by methylene blue staining assay Cytotoxicity against human SK-N-FI cells after 5 days by methylene blue staining assay	[PMID: 24183537]
SK-N-MC	IC₅₀	57.4 μM Compound: 6	Cytotoxicity against Homo sapiens (human) SK-N-MC cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) SK-N-MC cells after 72 hr by MTT assay	10.1007/s00044-010-9344-z
SK-N-SH	IC₅₀	6.4 μM Compound: Curcumin	Cytotoxicity against human SK-N-SH cells after 5 days by methylene blue staining assay Cytotoxicity against human SK-N-SH cells after 5 days by methylene blue staining assay	[PMID: 24183537]
SK-OV-3	IC₅₀	37.7 μM Compound: Curcumin	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 21215629]
SK-OV-3	IC₅₀	43.63 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 26174555]
SK-OV-3	IC₅₀	49.85 μM Compound: Curcumin	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 26873414]
SK-OV-3	IC₅₀	6.7 μM Compound: 1; CUR	Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay	[PMID: 31129455]
SMMC-7721	IC₅₀	12.57 μM Compound: 1; CUR	Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31129455]
SMMC-7721	IC₅₀	16.68 μM Compound: Curcumin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
SMMC-7721	IC₅₀	18.8 μM Compound: Curcumin	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
SMMC-7721	IC₅₀	19.47 μM Compound: Curcumin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
SMMC-7721	IC₅₀	39.42 μM Compound: CUR	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 25728027]
SW480	IC₅₀	10 μM Compound: Curcumin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric	[PMID: 30776692]
SW480	IC₅₀	10.17 μM Compound: Curcumin	Antiproliferative activity against human SW480 cells after 48 hrs by SRB assay Antiproliferative activity against human SW480 cells after 48 hrs by SRB assay	[PMID: 22889562]
SW480	IC₅₀	15 μM Compound: 1; CUR	Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay	[PMID: 31129455]
SW480	IC₅₀	17.94 μM Compound: CU	Cytotoxicity against human SW480 cells after 4 hrs by MTT assay Cytotoxicity against human SW480 cells after 4 hrs by MTT assay	[PMID: 31336310]
SW480	IC₅₀	18.13 μM Compound: Curcumin	Cytotoxicity against Homo sapiens (human) SW480 cell by MTT assay Cytotoxicity against Homo sapiens (human) SW480 cell by MTT assay	10.1007/s00044-010-9353-y
SW-620	GI₅₀	32 μM Compound: 15	Cytotoxicity against human SW620 cells after 48 hrs by WST1 assay Cytotoxicity against human SW620 cells after 48 hrs by WST1 assay	[PMID: 21183341]
SW-620	IC₅₀	>50 μM Compound: 1; CUR	Cytotoxicity against human SW620 Cells Cytotoxicity against human SW620 Cells	[PMID: 31129455]
SW-620	IC₅₀	12.52 μM Compound: CUR	Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
SW-620	IC₅₀	14 μM Compound: Curcumin	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 30138803]
T47D	IC₅₀	11 μM Compound: CU	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 31336310]
T47D	IC₅₀	19 μM Compound: Curc	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	30 μM Compound: Curcumin	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27517806]
T47D	IC₅₀	47.91 μM Compound: Curcumin	Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay	[PMID: 28319780]
T98G	IC₅₀	10 μM Compound: curcumin	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay	[PMID: 26631318]
T98G	IC₅₀	25 μM Compound: curcumin	Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26631318]
T98G	IC₅₀	25 μM Compound: 23, Curcumin	Anticancer activity against human T98G cells after 24 hrs by MTT assay Anticancer activity against human T98G cells after 24 hrs by MTT assay	[PMID: 20466556]
THP-1	IC₅₀	1.21 μM Compound: Curcumin	Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs	[PMID: 20561785]
THP-1	IC₅₀	199.63 nM Compound: Curcumin	Inhibition of tissue factor procoagulant activity in LPS-stimulated human THP1 cells preincubated for 1 hr before LPS addition measured after 5 hrs Inhibition of tissue factor procoagulant activity in LPS-stimulated human THP1 cells preincubated for 1 hr before LPS addition measured after 5 hrs	[PMID: 23199480]
THP-1	IC₅₀	199.63 nM Compound: Curcumin	Inhibition of tissue factor in Homo sapiens (human) THP1-cells using factor 10a chromogenic substrate assessed as inhibition of LPS-iduced procoagulant activity incubated for 1 hr prior to LPS-challenge measured after 5 hr by spectrophotometric analysis Inhibition of tissue factor in Homo sapiens (human) THP1-cells using factor 10a chromogenic substrate assessed as inhibition of LPS-iduced procoagulant activity incubated for 1 hr prior to LPS-challenge measured after 5 hr by spectrophotometric analysis	10.1007/s00044-012-0330-5
THP-1	IC₅₀	22.54 μM Compound: Curcumin	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
Thymocyte	IC₅₀	1.02 μM Compound: curcumin	Inhibition of H2O2-induced cell death of rat thymocyte assessed as cell viability Inhibition of H2O2-induced cell death of rat thymocyte assessed as cell viability	[PMID: 9599258]
U-251	IC₅₀	13.8 μM Compound: Curcumin	Cytotoxicity against human U251 cells after 48 hrs by MTT assay Cytotoxicity against human U251 cells after 48 hrs by MTT assay	[PMID: 21215629]
U-251	IC₅₀	15.26 μM Compound: 1; CUR	Cytotoxicity against human U251MG cells after 48 hrs by MTS assay Cytotoxicity against human U251MG cells after 48 hrs by MTS assay	[PMID: 31129455]
U-251	IC₅₀	25.81 μM Compound: 4	Cytotoxicity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
U-266	IC₅₀	7.57 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human U266 cells after 72 hrs by MTT assay Antiproliferative activity against human U266 cells after 72 hrs by MTT assay	[PMID: 24280069]
U2OS	EC₅₀	22.8 μM Compound: Curcumin	Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
U2OS	EC₅₀	34.4 μM Compound: Curcumin	Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
U-373MG ATCC	IC₅₀	>50 μM Compound: 1; CUR	Cytotoxicity against human U373MG Cells 48 hrs by MTS assay Cytotoxicity against human U373MG Cells 48 hrs by MTS assay	[PMID: 31129455]
U-373MG ATCC	IC₅₀	18 μM Compound: 23, Curcumin	Anticancer activity against human U373 cells after 24 hrs by MTT assay Anticancer activity against human U373 cells after 24 hrs by MTT assay	[PMID: 20466556]
U-87MG ATCC	IC₅₀	16 μM Compound: Curc	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-87MG ATCC	IC₅₀	18.4 μM Compound: Curcumin	Neurotoxicity in human U87 MG cells assessed as cell viability for 24 hrs by MTT assay Neurotoxicity in human U87 MG cells assessed as cell viability for 24 hrs by MTT assay	[PMID: 34391121]
U-87MG ATCC	IC₅₀	31.9 μM Compound: 2	Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37399711]
U-87MG ATCC	IC₅₀	7.15 μM Compound: 1; CUR	Cytotoxicity against human U87MG Cells 48 hrs by MTS assay Cytotoxicity against human U87MG Cells 48 hrs by MTS assay	[PMID: 31129455]
U-87MG ATCC	IC₅₀	8.1 μM Compound: Curcumin	Cytotoxicity against human U87MG cells after 5 days by methylene blue staining assay Cytotoxicity against human U87MG cells after 5 days by methylene blue staining assay	[PMID: 24183537]
U-937	IC₅₀	1.88 μM Compound: Curcumin	Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay	[PMID: 27040659]
Vero	CC₅₀	>250 μM Compound: 20	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	CC₅₀	0.054 μM Compound: Curcumin	Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	0.054 μM Compound: Curcumin	Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	0.054 μM Compound: Curcumin	Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	0.054 μM Compound: Curcumin	Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	0.054 μM Compound: Curcumin	Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	36.8 μM Compound: 35	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition Cytotoxicity against African green monkey Vero cells assessed as growth inhibition	[PMID: 29920454]
Vero	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay	[PMID: 20034711]
Vero	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	>0.01 μM Compound: Curcumin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	>10 μM Compound: 20	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	IC₅₀	10.97 μM Compound: 3	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32273215]
Vero	IC₅₀	17.87 μM Compound: 3	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32273215]
Vero	IC₅₀	22 μM Compound: curcumin	Cytotoxicity against african green monkey Vero cells after 72 hrs by crystal violet dye assay Cytotoxicity against african green monkey Vero cells after 72 hrs by crystal violet dye assay	[PMID: 19329324]
Vero	IC₅₀	25 μM Compound: 3	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32273215]
Vero	IC₅₀	35.05 μM Compound: 1	Cytotoxicity against african green monkey Vero cells by green fluorescent protein detection method Cytotoxicity against african green monkey Vero cells by green fluorescent protein detection method	[PMID: 24857542]
WiDr	IC₅₀	26.82 μM Compound: CU	Cytotoxicity against human WiDr cells after 4 hrs by MTT assay Cytotoxicity against human WiDr cells after 4 hrs by MTT assay	[PMID: 31336310]
WRL68	IC₅₀	27.8 μM Compound: CUR	Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
Y79	IC₅₀	30 μM Compound: Cur	Antiproliferative activity against human Y79 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human Y79 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33310285]

In Vitro

Curcumin exerts its chemopreventive effects partly through the activation of nuclear factor (erythroid-2 related) factor 2 (Nrf2) and its antioxidant and phase II detoxifying enzymes^[1].
Curcumin inhibits T47D cells growth, with IC₅₀s of 25, 19 and 17.5 μM for 24, 48 and 72 h MTT assays respectively. IC₅₀s of Curcumin and Silibinin (HY-N0779A) mixture against T47D cells, are 17.5, 15, and 12 μM for 24, 48, and 72 h exposure times, respectively^[2].
Curcumin (2.5-80 μM) induces apoptotic cell death in AGS and HT-29 cell lines, and the IC₅₀ values are 21.9, 40.7 μM, respectively, in both AGS and HT-29 cell lines. Curcumin-induced apoptosis requires caspase activities in AGS and HT-29 cells. Curcumin induces ER Ca²⁺ decline and mitochondrial Ca²⁺ overloading^[3].
Curcumin induces the G2/M cell cycle arrest of LNCaP and PC-3 cells in a dose dependent manner. Curcumin upregulates the protein level of NF-kappaB inhibitor IkappaBalpha and downregulates protein levels of c-Jun and AR^[5].
Curcumin (0 μM, 4 μM and 8 μM; for 24 h) can significantly inhibit the decrease in Bcl-2 gene expression caused by H2O2 and can significantly inhibit the increase in Bax and Caspase-3 gene expression induced by H₂O₂. Curcumin can alleviate apoptosis in bovine adipose-derived stem cells (ADSCs) induced by H₂O₂^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Curcumin (10 mg/kg, p.o.) significantly prevents decrease in the percentage of sucrose consumption, as compared to the CMS-exposed rats. Curcumin treatment results in significant prevention of increase in TNF-α and IL-6 levels in stressed rats^[4].
Curcumin decreases binding of p300/CREB-binding protein (CBP) at the brain-derived neurotrophic factor (BDNF) promoter at 20 mg/kg (i.p.), reduces binding of P300/CBP at the BDNF promoter at 40 mg/kg, and decreases binding all the four proteins of p300/CBP and H3K9ac/H4K5ac at the BDNF promoter at 60 mg/kg in chronic constriction injury (CCI) rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 458-37-7
Appearance Solid
Molecular Weight 368.38
Formel C₂₁H₂₀O₆
Color Yellow to orange
SMILES

O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
Synonyms

Diferuloylmethane; Natural Yellow 3; Turmeric yellow
Structure Classification
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (135)

All IFWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Imeta

2026 Feb 24.
Nat Cell Biol

Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay. [Abstract]

2021 Jan;23(1):40-48. PMID: 33420492
Theranostics

Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation. [Abstract]

2022 Jan 1;12(2):976-998. PMID: 34976224
J Exp Clin Cancer Res

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. [Abstract]

2018 Oct 29;37(1):261. PMID: 30373602

Curcumin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]

A375, A2058, and RPMI-7951 cells were treated with DMSO (control), Curcumin (25 μM), or Apigenin (30 μM) for 24 h. Apigenin and Curcumin induce apoptosis in melanoma cells.

Curcumin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]

The protein expression levels of cleaved PARP are detected from Curcumin and Apigenin-treated A375, A2058, and RPMI-7951 cell lysates compared to control samples using Western blotting analyses.

Curcumin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]

A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

Curcumin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]

A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

Curcumin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]

A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

Curcumin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]

Western analysis of PD-L1 expression in A375, A2058, and RPMI-7951 cells treated with IFN-γ, curcumin, or apigenin.
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2024 Dec 5:e2410360. PMID: 39639496
Sci Adv

Integrating hydrogels manipulate ECM deposition after spinal cord injury for specific neural reconnections via neuronal relays. [Abstract]

2024 Jul 5;10(27):eado9120. PMID: 38959311
Sci Adv

Chimeric apoptotic bodies functionalized with natural membrane and modular delivery system for inflammation modulation. [Abstract]

2020 Jul 22;6(30):eaba2987. PMID: 32832662
Chem Eng J

2026 May 19;540:177549.
Chem Eng J

2023 Sep 15, 472, 144901.
J Control Release

Improving the circulation time and renal therapeutic potency of extracellular vesicles using an endogenous ligand binding strategy. [Abstract]

2022 Dec:352:1009-1023. PMID: 36375619
Phytomedicine

Sparstolonin B and Curcumin alleviate atherogenesis by modulating T helper 17-stromal cell interactions associated with interleukin-17 receptor A (IL-17RA) - transforming growth factor-β-activated kinase 1 (TAK1) - nuclear factor-kappa B (NF-κB) signaling. [Abstract]

2025 Dec:149:157578. PMID: 41308385
Phytomedicine

Curcuminoids WM03 inhibits ovarian cancer cisplatin-resistant cells proliferation and reverses cisplatin resistance by targeting DYRK2. [Abstract]

2025 Jul:142:156632. PMID: 40315643
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Melittin suppresses ovarian cancer growth by regulating SREBP1-mediated lipid metabolism. [Abstract]

2025 Jan 2:137:156367. PMID: 39798341
Phytomedicine

Curcumin treatment suppresses cachexia-associated adipose wasting in mice by blocking the cAMP/PKA/CREB signaling pathway. [Abstract]

2023 Jan:109:154563. PMID: 36610148
Phytomedicine

Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling. [Abstract]

2021 Oct:91:153706. PMID: 34517264
Mater Today Bio

Nanoparticles coated with osteoblast-like cell membranes as curcumin delivery vehicles for targeted postmenopausal osteoporosis therapy. [Abstract]

2025 Dec 9:36:102636. PMID: 41497898
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
Oncogene

BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. [Abstract]

2021 Apr;40(15):2711-2724. PMID: 33712705
Int J Biol Macromol

Effects of colloidal delivery systems for curcumin-Brassica rapa L. polysaccharide mixture encapsulation on physicochemical properties, stability, and gut microbiota modulation. [Abstract]

2026 Jun 21:153147. PMID: 42324006
Regen Biomater

Curcumin-primed milk-derived extracellular vesicles remodel hair follicle microenvironment for the treatment of androgenetic alopecia. [Abstract]

2025 May 30:12:rbaf051. PMID: 40735523
Int J Biol Macromol

Curcumin-loaded platelets with hydroxypropyl chitin hydrogel composite system through photo-activation for effective hemostasis management and wound healing. [Abstract]

2025 May 16:144291. PMID: 40383331
Int J Biol Macromol

Fabrication and characterization of curcumin-loaded nanoparticles using licorice protein isolate from Radix Glycyrrhizae. [Abstract]

2024 Jan:255:128235. PMID: 37981268
Mol Med

Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword. [Abstract]

2025 Jun 5;31(1):221. PMID: 40468178
Mol Med

Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect and potential mechanism of nomilin against triple-negative breast cancer. [Abstract]

2024 Sep 28;30(1):166. PMID: 39342122
Antioxidants (Basel)

Curcumin Alleviates Singapore Grouper Iridovirus-Induced Intestine Injury in Orange-Spotted Grouper (Epinephelus coioides). [Abstract]

2023 Aug 9;12(8):1584. PMID: 37627579
Phytother Res

Curcumin Alleviates the Osteogenesis Inhibition and the Aging Process in BMSCs Induced by Iron Overload Through Activating the NRF2/GPX4 Pathway. [Abstract]

2026 Jul;40(7):4188-4205. PMID: 42046471
Br J Pharmacol

Curcumin controls lysosomal acidification and exocytosis to ameliorate lysosomal cholesterol accumulation in Niemann-Pick type C disease. [Abstract]

2026 Apr 26. PMID: 42036241
Br J Pharmacol

A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation. [Abstract]

2023 Aug;180(15):1930-1948. PMID: 36788033
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
J Med Chem

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. [Abstract]

2023 Mar 23;66(6):4106-4130. PMID: 36876904
Int J Oncol

Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. [Abstract]

2023 Jan;62(1):8. PMID: 36416310
J Ethnopharmacol

Eupalinolide B ameliorates liver fibrosis by targeting PKCα to suppress the AKT/mTOR axis in hepatic stellate cells. [Abstract]

2026 May 23:363:121421. PMID: 41759558
J Ethnopharmacol

Chalcone derivatives from licorice inhibit human and rat gonadal 3β-hydroxysteroid dehydrogenases as therapeutic uses. [Abstract]

2023 Dec 5:317:116690. PMID: 37245711
J Ethnopharmacol

Curcuminoids inhibit human and rat placental 3β-hydroxysteroid dehydrogenases: Structure-activity relationship and in silico docking analysis. [Abstract]

2023 Apr 6:305:116051. PMID: 36572324
J Agric Food Chem

Curcumin Activates the Wnt/β-Catenin/PPARD Signaling Axis to Attenuate Ochratoxin A-Induced Enterotoxicity. [Abstract]

2025 Dec 24. PMID: 41439788
J Agric Food Chem

Curcumin Alleviates Bisphenol A-Induced Blood-Testis Barrier Disruption in Mice by Targeting Surfactant Protein B (SFTPB) to Suppress Oxidative Stress-Activated NLRP3 Inflammasome. [Abstract]

2025 Nov 19;73(46):29874-29885. PMID: 41212106
J Agric Food Chem

Ginsenoside RK1 Promotes Hepatic Stellate Cell Glycolysis-Mediated Ferroptosis by Activating the HK2/ACSL4/LPCAT3/ALOX5 Signaling Pathway. [Abstract]

2025 Jul 9;73(27):17205-17218. PMID: 40570179
Ecotoxicol Environ Saf

Synergistic effects of botanical curcumin-induced programmed cell death on the management of Spodoptera litura Fabricius with avermectin. [Abstract]

2022 Jan 1:229:113097. PMID: 34942422
Ecotoxicol Environ Saf

Antagonizing effects of curcumin against mercury-induced autophagic death and trace elements disorder by regulating PI3K/AKT and Nrf2 pathway in the spleen. [Abstract]

2021 Oct 1:222:112529. PMID: 34293585
Bioresour Bioprocess

Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study. [Abstract]

2024 Nov 27;11(1):108. PMID: 39604740
Liver Int

Curcumin Targets Crispld2 to Suppress Hepatic Stellate Cell Activation via PI3K/AKT Pathway Inhibition in Hepatic Fibrosis. [Abstract]

2026 Jun;46(6):e70696. PMID: 42130159
Drug Des Devel Ther

Network Pharmacology and Metabolomics Reveal Anti-Ferroptotic Effects of Curcumin in Acute Kidney Injury. [Abstract]

2024 Dec 21:18:6223-6241. PMID: 39722679
Drug Des Devel Ther

Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats. [Abstract]

2018 Dec 3:12:4095-4105. PMID: 30584274
Foods

Curcumin-Mediated Sono-Photodynamic Treatment Inactivates Listeria monocytogenes via ROS-Induced Physical Disruption and Oxidative Damage. [Abstract]

2022 Mar 11;11(6):808. PMID: 35327232
Commun Biol

CCAAT/enhancer binding protein beta (C/EBPβ) regulates the formation of the ovarian reserve. [Abstract]

2025 Sep 30;8(1):1394. PMID: 41028284
J Zhejiang Univ Sci B

Single-cell RNA-sequencing-guided reactive oxygen species-scavenging hydrogel design for regeneration of osteoporotic bone. [Abstract]

2025 Dec 31;26(12):1172-1191. PMID: 41490726
Respir Res

REDD1 mediates HDM-induced nuclear-cytoplasmic translocation and release of IL-33 in airway epithelial cells by downregulating Nrf2. [Abstract]

2025 Feb 1;26(1):47. PMID: 39893427
Int Immunopharmacol

Targeting the TLR4/PAD4-mediated formation of macrophage extracellular traps by curcumin attenuates plaque destabilization in ulcerative colitis-associated atherosclerosis. [Abstract]

2026 Jun 15:179:116616. PMID: 41997051
Int Immunopharmacol

Pedunculoside ameliorates liver fibrosis by targeting c-Jun to inhibit hepatic stellate cell activation. [Abstract]

2026 Jun 15:179:116602. PMID: 41936306
Int J Mol Sci

Synergistic Effects of a Novel Combination of Natural Compounds Prevent H2O2-Induced Oxidative Stress in Red Blood Cells. [Abstract]

2025 Feb 5;26(3):1334. PMID: 39941102
Int Immunopharmacol

Curcumin activates the Wnt/β-catenin signaling pathway to alleviate hippocampal neurogenesis abnormalities caused by intermittent hypoxia: A study based on network pharmacology and experimental verification. [Abstract]

2024 Dec 25;143(Pt 1):113299. PMID: 39362017
Int Immunopharmacol

A synergistic effect of triptolide and curcumin on rheumatoid arthritis by improving cell proliferation and inducing cell apoptosis via inhibition of the IL-17/NF-κB signaling pathway. [Abstract]

2024 Sep 2;142(Pt A):112953. PMID: 39226828
Int J Mol Sci

Systematic Analysis of the BrHAT Gene Family and Physiological Characteristics of Brassica rapa L. Treated with Histone Acetylase and Deacetylase Inhibitors under Low Temperature. [Abstract]

2024 Aug 24;25(17):9200. PMID: 39273148
Int J Mol Sci

Cinnamic Acid, Perillic Acid, and Tryptophan Metabolites Differentially Regulate Ion Transport and Serotonin Metabolism and Signaling in the Mouse Ileum In Vitro. [Abstract]

2024 Jun 18;25(12):6694. PMID: 38928404
Int J Mol Sci

Metabolomics and Transcriptomics Analyses of Curcumin Alleviation of Ochratoxin A-Induced Hepatotoxicity. [Abstract]

2023 Dec 21;25(1):168. PMID: 38203339
Infect Dis Ther

Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells. [Abstract]

2021 Mar;10(1):483-494. PMID: 33532909
Int J Mol Sci

Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells. [Abstract]

2019 Jan; 20(1): 28. PMID: 30577600
Biogerontology

Curcumin attenuates PM2.5-triggered pulmonary senescence via the mTOR/S6K1 signaling pathway. [Abstract]

2026 Jan 3;27(1):31. PMID: 41484271
J Enzyme Inhib Med Chem

Curcumin analogues exert potent inhibition on human and rat gonadal 3β-hydroxysteroid dehydrogenases as potential therapeutic agents: structure-activity relationship and in silico docking. [Abstract]

2023 Dec;38(1):2205052. PMID: 37184069
Biochim Biophys Acta Mol Basis Dis

Curcumin protects against PIICS-induced liver injury by suppressing iron-induced lipid peroxidation: Insights from network pharmacology and experimental validation. [Abstract]

2025 Sep 19;1872(1):168053. PMID: 40975907
Mol Med Rep

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. [Abstract]

2023 Jan;27(1):17. PMID: 36453238
Mol Med Rep

A SIRT1 agonist reduces cognitive decline in type 2 diabetic rats through antioxidative and anti‑inflammatory mechanisms. [Abstract]

2019 Feb;19(2):1040-1048. PMID: 30483738
Sci Rep

Loss of Brg1 prevents the progression of pulmonary hypertension by inhibiting Nrf2 expression. [Abstract]

2026 Jun 3. PMID: 42236527
Mol Pharm

Curcumin-Loaded Liposomes (hPLipo/Cur) with Liver-Targeting Properties for Efficient NAFLD Treatment by Alleviating Mitochondrial ROS-Mediated Ferroptosis via NRF2 Pathway. [Abstract]

2026 Apr 6;23(4):2398-2411. PMID: 41725216
Sci Rep

Synthesis and performance optimization of multi-bioactive compound-loaded nanocarriers for antimicrobial applications. [Abstract]

2025 Nov 21;15(1):41324. PMID: 41271794
Sci Rep

Synergistic antibacterial activity of curcumin and phage against multidrug-resistant Acinetobacter baumannii. [Abstract]

2025 Mar 15;15(1):8959. PMID: 40089540
Cell Div

Curcumin enhances ATG3-dependent autophagy and inhibits metastasis in cervical carcinoma. [Abstract]

2024 Nov 28;19(1):33. PMID: 39609925
Eur J Med Res

NF-κB-mediated enhancement of H3K27me3 through EZH2: a mechanism to suppress pyocyanin-induced autophagy in macrophages. [Abstract]

2025 Apr 29;30(1):346. PMID: 40301947
Nanomaterials

A Curcumin-Decorated Nanozyme with ROS Scavenging and Anti-Inflammatory Properties for Neuroprotection. [Abstract]

2024 Feb 20;14(5):389. PMID: 38470720
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
Cell Signal

Curcumin alleviates lipopolysaccharide-induced alveolar epithelial Glycocalyx damage by modulating the Rac1/NF-κB/HPSE pathway. [Abstract]

2025 May 27:111909. PMID: 40441470
J Cell Mol Med

Indispensable role of mitochondria in maintaining the therapeutic potential of curcumin in acute kidney injury. [Abstract]

2021 Oct;25(20):9863-9877. PMID: 34532973
Acta Biochim Biophys Sin (Shanghai)

Curcumin suppresses head and neck squamous cell carcinoma progression via NCOA4-FTH1-mediated ferroptosis. [Abstract]

2026 May 27. PMID: 42271129
Poult Sci

Inhibitory effect of curcumin on duck tembusu virus. [Abstract]

2025 May 31;104(8):105381. PMID: 40466261
Aquaculture

15 January 2023, 738870.
FASEB J

1-Naphthol Drives Liver Steatosis and Fibrosis via the CA3-CD36 Axis Independent of Obesity. [Abstract]

2026 Jun 15;40(11):e71960. PMID: 42201771
Biology (Basel)

Curcumin and Selenium Synergistically Alleviate Oxidative Stress in IPEC-J2 Cells and ICR Mice. [Abstract]

2025 Aug 23;14(9):1117. PMID: 41007264
FASEB J

Molecular and functional characterization of an evolutionarily conserved CREB-binding protein in the Lymnaea CNS. [Abstract]

2022 Nov;36(11):e22593. PMID: 36251357
FASEB J

Butyrate drives the acetylation of histone H3K9 to activate steroidogenesis through PPARγ and PGC1α pathways in ovarian granulosa cells. [Abstract]

2021 Feb;35(2):e21316. PMID: 33433947
FASEB J

Cystic fibrosis transmembrane conductance regulator mediates tenogenic differentiation of tendon-derived stem cells and tendon repair: accelerating tendon injury healing by intervening in its downstream signaling. [Abstract]

2017 Sep;31(9):3800-3815. PMID: 28495756

Curcumin purchased from MedChemExpress. Usage Cited in: FASEB J. 2017 Sep;31(9):3800-3815. [Abstract]

Expression of CFTR after treatment with Curcumin (10 μM) for 3 d is assayed by Western blotting. TDSCs from WT mice are treated with Curcumin (10 μM) for 3 d and results show that CFTR expression is increased at the protein level.
Antimicrob Agents Chemother

Zafirlukast, as a viral inactivator, potently inhibits infection of several flaviviruses, including Zika virus, dengue virus, and yellow fever virus. [Abstract]

2024 May 29:e0016824. PMID: 38809067
Fish Shellfish Immunol

Modulatory effects of curcumin on Singapore grouper iridovirus infection-associated apoptosis and autophagy in vitro. [Abstract]

2022 Dec:131:84-94. PMID: 36206994
Eur J Immunol

Neutralization of IL-10 produced by B cells promotes protective immunity during persistent HCV infection in humanized mice. [Abstract]

2020 Sep;50(9):1350-1361. PMID: 32339264
J Photochem Photobiol B

Curcumin-mediated photodynamic action disturbs TOM70-depedent MIC60 import to damage mitonchondria against breast cancer. [Abstract]

2025 Dec 11:274:113339. PMID: 41418387
Naunyn Schmiedebergs Arch Pharmacol

Analysis of the mechanism of curcumin against osteoarthritis using metabolomics and transcriptomics. [Abstract]

2024 May;397(5):3313-3329. PMID: 37938371
Viruses

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator. [Abstract]

2022 Apr 21;14(5):861. PMID: 35632604
Food Agr Immunol

28 Aug 2022.
J Cosmet Dermatol

Curcumin alleviates hypertrophic scarring by inhibiting fibroblast activation and regulating tissue inflammation. [Abstract]

2024 Jan;23(1):227-235. PMID: 37400988
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Exp Cell Res

CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein. [Abstract]

2020 Mar 15;388(2):111876. PMID: 31991125
J Cancer Res Clin Oncol

Curcumin promotes ferroptosis in hepatocellular carcinoma via upregulation of ACSL4. [Abstract]

2024 Sep 23;150(9):429. PMID: 39311951
Mol Biotechnol

Curcumin Inhibits Lipopolysaccharide-Induced Inflammation Through the HMGB1/NF-κB Signaling Pathway to Promote the Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells. [Abstract]

2025 May 1. PMID: 40310592
Mol Cell Probes

The role of miR-21/RECK in the inhibition of osteosarcoma by curcumin. [Abstract]

2020 Jun;51:101534. PMID: 32081769
Exp Eye Res

Curcumin ameliorates benzalkonium chloride-induced dry eye disease in mice. [Abstract]

2025 Oct:259:110509. PMID: 40633646
Front Vet Sci

Curcumin and selenium synergistically mitigate oxidative stress in white-feathered broilers. [Abstract]

2025 Jun 2:12:1600466. PMID: 40530034
J Steroid Biochem Mol Biol

Cyclocurcumin potently inhibits human aromatase as a potential therapeutic agent. [Abstract]

2024 Dec 31:106672. PMID: 39746524
Tissue Cell

Curcumin triggers the Wnt/β-catenin pathway and shields neurons from injury caused by intermittent hypoxia. [Abstract]

2024 Dec:91:102587. PMID: 39454474
Exp Eye Res

Curcumin protects retinal neuronal cells against oxidative stress-induced damage by regulating mitochondrial dynamics. [Abstract]

2022 Nov:224:109239. PMID: 36067824
J Cell Biochem

Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor-kappa B signaling. [Abstract]

2019 Apr;120(4):6718-6728. PMID: 30592318

Curcumin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Apr;120(4):6718-6728. [Abstract]

Western analysis of the expression of NLRP3, pro-casp-1, casp-1, pro-1β, IL-1β in the treatment with or without Curcumin, DMSO, MSU and Colchicine.
Fitoterapia

Topical application of Calvatia lilacina ethanol extract-derived fraction promotes diabetic wound healing. [Abstract]

2026 Mar:189:107087. PMID: 41485691
Theriogenology

Enhancing porcine oocyte quality and embryo development through natural antioxidants. [Abstract]

2025 Jan 15:232:96-108. PMID: 39536623
Toxicol Res (Camb)

A curcumin analog CA-5f inhibits urokinase-type plasminogen activator and invasive phenotype of triple-negative breast cancer cells. [Abstract]

2021 Nov 17;38(1):19-26. PMID: 35070937
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
SAR QSAR Environ Res

Potent inhibition of human and rat 17β-hydroxysteroid dehydrogenase 1 by curcuminoids and the metabolites: 3D QSAR and in silico docking analysis. [Abstract]

2024 May 24:1-24. PMID: 38785078
Physiol Res

Curcumin in vitro Neuroprotective Effects Are Mediated by p62/keap-1/Nrf2 and PI3K/AKT Signaling Pathway and Autophagy Inhibition. [Abstract]

2023 Aug 31;72(4):497-510. PMID: 37795892
Vet Microbiol

Curcumin inhibits classical swine fever virus replication by interfering with lipid metabolism. [Abstract]

2021 Aug;259:109152. PMID: 34146894
Technol Cancer Res Treat

Targeting laryngeal cancer cells with 5-fluorouracil and curcumin using mesoporous silica nanoparticles. [Abstract]

Jan-Dec 2020;19:1533033820962114. PMID: 33267716
J Nat Med

Xanthohumol attenuates TXNIP-mediated renal tubular injury in vitro and in vivo diabetic models. [Abstract]

2025 Mar;79(2):314-327. PMID: 39752106
Virology

Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells. [Abstract]

2021 Aug:560:96-109. PMID: 34051479
Biochem Biophys Res Commun

Curcumin ameliorates high-glucose-induced lipid accumulation in HepG2 cells via AMPK activation and mTOR suppression. [Abstract]

2025 Oct 27:790:152879. PMID: 41172806
Biochem Biophys Res Commun

Network pharmacology, molecular docking and experimental study on the mechanism of Curcumin's anti-ferroptosis in melanocytes. [Abstract]

2024 Dec 3:736:150871. PMID: 39461013
Onco Targets Ther

Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway. [Abstract]

2019 May 17:12:3893-3903. PMID: 31190888
Exp Ther Med

Curcumin ameliorates H2O2-induced inflammatory response in chondrocytes by inducing autophagy activation. [Abstract]

2022 Apr;23(4):272. PMID: 35251338
Oncol Lett

Curcumin induces and enhances the PARP1-mediated parthanatos in diffuse large B cell lymphoma. [Abstract]

2026 Mar 30;31(5):199. PMID: 41969587
Oncol Lett

Leucovorin enhances curcumin-induced inhibition of cell viability and ferroptosis in colorectal cancer cells. [Abstract]

2026 Mar 4;31(5):155. PMID: 41852897
Transl Cancer Res

Extracellular vesicles isolated from curcumin-medium weakened RKO cell proliferation and migration. [Abstract]

2024 Jun 30;13(6):2596-2604. PMID: 38988906
Anticancer Drugs

Research on curcumin mediating immunotherapy of colorectal cancer by regulating cancer associated fibroblasts. [Abstract]

2025 Jan 1;36(1):72-78. PMID: 39264802
Medicine

Curcumin protects PC12 cells from a high glucose-induced inflammatory response by regulating the miR-218-5p/TLR4 axis. [Abstract]

2022 Oct 7;101(40):e30967. PMID: 36221434
Am J Transl Res

Curcumin promotes the survival of ischemic random skin flaps via autophagy. [Abstract]

2021 Mar 15;13(3):1337-1351. PMID: 33841660
Cancer Biomark

Curcumin inhibits proliferation of hepatocellular carcinoma cells through down regulation of DJ-1. [Abstract]

2020;29(1):1-8. PMID: 32417759
Rev Bras Farmacogn

13 September 2022.
JMIR Res Protoc

Efficient Generation of Chondrocytes From Bone Marrow-Derived Mesenchymal Stem Cells in a 3D Culture System: Protocol for a Practical Model for Assessing Anti-Inflammatory Therapies. [Abstract]

2023 Jul 28:12:e42964. PMID: 37505889
Gastroenterol Res Pract

Study of the Mechanism by Which Curcumin Cooperates with Sestrin2 to Inhibit the Growth of Pancreatic Cancer. [Abstract]

2021 Jun 30:2021:7362233. PMID: 34306067
Eur J Inflamm

December 1, 2021.
Res Sq

2026 Jun 17.
bioRxiv

2025 July 14.
Patent

US20250127769A1.
University of Wyoming

2025.
bioRxiv

2025 February 22.
SSRN

2024 Jun 02.
Research Square Preprint

2023 May 4.

Curcumin purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2023 May 4.

Curcumin (5, 10, 20, 40, 50 µM; 24 h) inhibits the viability of Hs578T cells in a concentration-dependent manner.

Curcumin purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2023 May 4.

Curcumin (20 µM; 24 h) significantly inhibits the protein expression of Fibronectin, mTOR, β-Catenin, p-Akt, Akt, N-Cadherin, p-S6, and S6 in Hs578T cells.
Oxid Med Cell Longev

Curcumin Ameliorates Age-Induced Tight Junction Impaired in Porcine Sertoli Cells by Inactivating the NLRP3 Inflammasome through the AMPK/SIRT3/SOD2/mtROS Signaling Pathway. [Abstract]

2023 Feb 17:2023:1708251. PMID: 36846717
Biomed Pharmacother

Curcumin exerts chondroprotective effects against osteoarthritis by promoting AMPK/PINK1/Parkin-mediated mitophagy. [Abstract]

2022 May 10;151:113092. PMID: 35550528
Aging (Albany NY)

Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway. [Abstract]

2021 Jul 29;13(14):18757-18768. PMID: 34324434

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (271.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7146 mL

13.5729 mL

27.1459 mL

5 mM

0.5429 mL

2.7146 mL

5.4292 mL

10 mM

0.2715 mL

1.3573 mL

2.7146 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3 mg/mL (8.14 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

T47D breast cancer cell line is grown in RPMI 1640 supplemented with 10% FBS, 2 mg/mL sodium bicarbonate, 0.05 mg/mL penicillin G, 0.08 mg/mL streptomycin. Culture is maintained on plastic flask and incubated at 37°C in 5% CO₂. After growing sufficient amount of cells, cytotoxic effect of silibinin and curcumin is studied by 24, 48 and 72 h MTT assays in which 1000 cell/well are cultivated in a 96 well plate. After 24 h incubation in 37°C with humidified atmosphere containing 5% CO₂, the cells are treated with serial concentrations of curcumin (5, 10, 20, 30, 40, 50, 60, 80, 100 µM), silibinin (20, 40, 60, 80, 100, 120, 140, 180, 200 µM), and curcumin-silibinin mixture (each of them 5, 10, 20, 30, 40, 50, 60, 80, 100 µM) for 24, 48 and 72 h in the quadruplicate manner, in addition to cells with 200 μL culture medium containing 10% DMSO for control. After incubation, the medium of all wells of the plate are exchanged with fresh medium and the cells are leaved for 24 h in incubator. Then, medium of all wells are removed carefully and 50 μL of 2 mg/mL MTT dissolved in PBS is added to each wells and the plate is covered with aluminum foil and incubated for 4.5 h again. After removing content of the wells, 200 μL pure DMSO is added to the wells. Then, 25 μL Sorensen’s glycine buffer is added and immediately absorbance of each wells is read in 570 nm using EL×800 Microplate Absorbance Reader with reference wavelength of 630 nm.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Curcumin (10 mg/kg), freshly suspended in saline, is administrated by oral gavage once a day for 3 weeks. Forty rats are randomLy assigned to 4 groups (n=10/each group): group I receives saline and serves as control, group II receives curcumin, group III is exposed to CMS andreceive saline and group IV are subjected to CMS andreceive curcumin.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Gao S, et al. Curcumin attenuates arsenic-induced hepatic injuries and oxidative stress in experimental mice through activation of Nrf2 pathway, promotion of arsenic methylation and urinary excretion. Food Chem Toxicol. 2013 Jul 18. pii: S0278-6915(13)004 [Content Brief]

[2]. Nasiri M, et al. Curcumin and Silibinin Inhibit Telomerase Expression in T47D Human Breast Cancer Cells. Asian Pac J Cancer Prev. 2013;14(6):3449-53. [Content Brief]

[3]. Cao A, et all. Curcumin induces apoptosis in human gastric carcinoma AGS cells and colon carcinoma HT-29 cells through mitochondrial dysfunction and endoplasmic reticulum stress. Apoptosis. 2013 Jul 24. [Epub ahead of print] [Content Brief]

[4]. Jiang H, et al. Antidepressant-like effects of curcumin in chronic mild stress of rats: Involvement of its anti-inflammatory action. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 20. pii: S0278-5846(13)00150-4. [Content Brief]

[5]. Guo H, et al. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor. Pharmazie. 2013 Jun;68(6):431-4. [Content Brief]

[6]. Zhu X, et al. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model. PLoS One. 2014 Mar 6;9(3):e91303. [Content Brief]

[7]. Balasubramanyam K, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004 Dec 3;279(49):51163-71. [Content Brief]

[8]. Jun Wan Shin, et al. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification. Biochem Pharmacol. 2020 Mar;173:113820. [Content Brief]

[9]. Lucas D. Dias, et al. Curcumin as a photosensitizer: From molecular structure to recent advances in antimicrobial photodynamic therapy. Journal of Photochemistry and Photobiology C: Photochemistry Reviews. Volume 45, December 2020, 100384.

[10]. Jiang E,et al. Curcumin Inhibits Oxidative Stress and Apoptosis Induced by H2O2 in Bovine Adipose-Derived Stem Cells (bADSCs). Animals (Basel). 2024 Nov 26;14(23):3421. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7146 mL	13.5729 mL	27.1459 mL	67.8647 mL
	5 mM	0.5429 mL	2.7146 mL	5.4292 mL	13.5729 mL
	10 mM	0.2715 mL	1.3573 mL	2.7146 mL	6.7865 mL
	15 mM	0.1810 mL	0.9049 mL	1.8097 mL	4.5243 mL
	20 mM	0.1357 mL	0.6786 mL	1.3573 mL	3.3932 mL
	25 mM	0.1086 mL	0.5429 mL	1.0858 mL	2.7146 mL
	30 mM	0.0905 mL	0.4524 mL	0.9049 mL	2.2622 mL
	40 mM	0.0679 mL	0.3393 mL	0.6786 mL	1.6966 mL
	50 mM	0.0543 mL	0.2715 mL	0.5429 mL	1.3573 mL
	60 mM	0.0452 mL	0.2262 mL	0.4524 mL	1.1311 mL
	80 mM	0.0339 mL	0.1697 mL	0.3393 mL	0.8483 mL
	100 mM	0.0271 mL	0.1357 mL	0.2715 mL	0.6786 mL

Keywords

Curcumin

135 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Curcumin

Anti-Infection Compound Library

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Food Additive Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Anti-Aging Natural Product Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Radiosensitizer Library

Mitophagy Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library